




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : A61K 31/155, 31/195, 31/415, 31/70, 35/00, G01N 33/58, 33/68		A1	(11) International Publication Number: WO 94/20083 (43) International Publication Date: 15 September 1994 (15.09.94)
(21) International Application Number: PCT/US93/10880 (22) International Filing Date: 12 November 1993 (12.11.93) (30) Priority Data: 08/029,417 11 March 1993 (11.03.93) US		(81) Designated States: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant: THE PICOWER INSTITUTE FOR MEDICAL RESEARCH [US/US]; 350 Community Drive, Manhasset, NY 11030 (US). (72) Inventors: BUCALA, Richard, J.; Apartment 33-0, 504 East 63rd Street, New York, NY 10021 (US). VLASSARA, Helen; Ram Island Drive, Shelter Island, NY 11964 (US). CERAMI, Anthony; Ram Island Drive, Shelter Island, NY 11964 (US). (74) Agent: JACKSON, David, A.; Klauber & Jackson, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).		Published With international search report.	

(54) Title: GLYCOSYLATION OF LIPIDS AND LIPID-CONTAINING PARTICLES, AND DIAGNOSTIC AND THERAPEUTIC METHODS AND MATERIALS DERIVED THEREFROM



## (57) Abstract

The *in vivo* oxidation of lipids and lipid-containing molecules has been discovered to be initiated by the concurrent reaction of such lipid materials with reducing sugars such as glucose, advanced glycosylation endproducts such as AGE-peptides, or a compound which forms advanced glycosylation endproducts, to form materials or particles known as AGE-lipids. AGE-lipids have been implicated in the aging process, the abnormal formation of lipofuscin and in various disease states such as diabetes and atherosclerosis. Diagnostic methods are contemplated, extending in utility from the detection of the onset and course of conditions in which variations in lipid oxidation, AGE-lipid levels, LDL levels, apolipoprotein levels, apolipoprotein receptor binding the like, may be measured, to drug discovery assays. Corresponding methods of treatment and pharmaceutical compositions are disclosed that are based on an active ingredient or ingredients that demonstrate the ability to modulate the levels of all the foregoing markers of lipid oxidation.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**GLYCOSYLATION OF LIPIDS AND LIPID-CONTAINING PARTICLES,  
AND DIAGNOSTIC AND THERAPEUTIC METHODS AND MATERIALS  
DERIVED THEREFROM**

5 This invention was made with partial assistance from  
grant Nos. AGO-9453, AGO-6943 and DK 19655-15 from the  
National Institutes of Health. The government may have  
certain rights in this invention.

10 RELATED PUBLICATIONS

The Applicants are co-authors of the following articles  
directed to the subject matter of the present invention:  
Bucala, R., et al., "Glucose Reacts With Phospholipids to  
15 Initiate Advanced Glycosylation and Fatty Acid Oxidation:  
Mechanism for the Oxidative Modification of LDL *In Vivo*,  
(submitted).

TECHNICAL FIELD OF THE INVENTION

20

The present invention relates generally to the non-  
enzymatic glycosylation of proteins and other  
biomolecules and the often consequent formation of  
advanced glycosylation endproducts (AGEs), and  
25 particularly to the formation of lipid-AGEs and the role  
that glycosylated lipids and lipoproteins may play as  
markers and actors in conditions such as atherosclerosis  
and diabetes.

30

BACKGROUND OF THE INVENTION

Glucose and other reducing sugars attach non-  
enzymatically to the amino groups of proteins in a  
concentration-dependent manner. Over time, these initial  
35 Amadori adducts undergo further rearrangements,  
dehydrations and cross-linking with other proteins to  
accumulate as a family of complex structures which are  
referred to as Advanced Glycosylation Endproducts (AGEs).

Beginning with the early work of the present applicants and extending to the present, substantial progress has been made toward the elucidation of the role and clinical significance of advanced glycosylation endproducts, so  
5 that it is now acknowledged that many of the conditions heretofore attributed to the aging process or to the pathological effects of diseases such as diabetes, are attributable at least in part to the formation of AGEs *in vivo*.

10

Advanced glycosylation tends to occur on molecules with long half-lives, under conditions of relatively high sugar concentration, such as in diabetes mellitus. Numerous studies have suggested that AGEs play an  
15 important role in the structural and functional alteration which occurs during aging and in chronic disease. Additionally, advanced glycosylation endproducts are noted to form more rapidly in diabetic and other diseased tissue than in normal tissue..

20

A particular area that has received attention in light of the series of discoveries regarding the relationship of advanced glycosylation of proteins to the etiology of conditions such as diabetes and aging, has been the set  
25 of events that coincide in the development of vascular disease. Specifically, the formation of atherosclerotic lesions and plaques is an example of a condition that has been extensively investigated with a view to elucidating the interrelationship, if any, that exists between the  
30 oxidation of low density lipoproteins (LDL) and the presence and formation of AGEs.

Oxidation of the lipid component of low-density lipoprotein (LDL) results in the loss of the recognition  
35 of the apo B component by cellular LDL receptors, and in the preferential uptake of oxidized-LDL(ox-LDL) by macrophage "scavenger" receptors. The enhanced

endocytosis of ox-LDL by vascular wall macrophages transforms them into lipid-laden foam cells that characterize early atherosclerotic lesions.

- 5 Previous studies have suggested that AGE modification of LDLs increases the potential for lipid oxidation. The "family" of AGEs includes species which can be isolated and characterized by chemical structure; some being quite stable, while others are unstable or reactive. AGE-  
10 lipids may also be stable, unstable or reactive.

When used with reference to endogenous lipids, AGE-lipid compounds are typically formed non-enzymatically *in vivo*. However, AGE-lipid compounds can also be produced *in*  
15 *vitro* by, e.g., incubating a mixture of a reducing sugar and a suitable lipid, e.g., a lipid bearing an amino group, or by other methods *in vitro*, such as chemical coupling of AGEs and AGE models to biological macromolecules.

- 20 The reaction between reducing sugars and the reactive groups of lipids may initiate the advanced glycosylation process. This process typically begins with a reversible reaction between the reducing sugar and the reactive  
25 group to form a Schiff base, which proceeds to form a covalently-bonded Amadori rearrangement product. Once formed, the Amadori product undergoes further rearrangement to produce the AGE-modified compound.

- 30 Although these reactions occur slowly, lipids may accumulate a measurable amount of AGEs *in vivo*. The resulting AGE-lipids may reduce the structural and/or functional integrity of organs and organ parts, modify the metabolism, or otherwise reduce or impair host  
35 function.

Picard et al. (1992) *Proc. Natl. Acad. Sci. USA*, 89:6876-6880, studied the reaction between malonyl dialdehyde (MDA) and apolipoprotein B (apo B), a protein component of LDL, and performed experiments to determine the ability of aminoguanidine to bind preferentially to MDA to prevent its conjugation to apo B. To establish the environment for these experiments, the authors induced lipid peroxidation by incubation with endothelial cells or with  $\text{Cu}^{2+}$ . However, the Picard et al. experiments are limited by the specific *in vitro* environment chosen, as the physiological oxidation of lipids to form the reactive aldehydes to which aminoguanidine is confirmed to bind will not occur by the means utilized in the article.

More particularly, *in vitro* studies suggest that the oxidative modification of lipids proceeds via free radical-mediated oxidation of unsaturated bonds that are present within fatty acid residues (12, 13). Polyunsaturated fatty acids are particularly sensitive to oxidation because methylene hydrogens located between paired double bonds are easily abstracted by radical-catalyzed reactions. Diene conjugation occurs and hydroperoxides form. This is followed by fatty acid decomposition, the formation of reactive aldehydes, and in the case of LDL, the covalent modification of apoprotein residues (12, 14, 15).

The biochemical processes that initiate lipid oxidation *in vivo* remain poorly understood. Triplet oxygen is a poor oxidant under normal, physiological conditions and significant oxidation of LDL *in vitro* occurs only after the addition of micromolar concentrations of divalent metals such as copper. Lipid oxidation is prevented completely in these incubations by the inclusion of metal chelators such as EDTA (15). LDL oxidation also occurs in diverse cell culture systems and can be inhibited

partially by pharmacological blockade of cellular lipxygenases (16). The precise role of reactive oxygen species in the oxidative modification of lipids *in vivo* has not been determined, however. Low trace metal concentrations, the high availability of ligands that form tight coordination complexes with metals, and the abundant anti-oxidant capacity of plasma suggest that metal-catalyzed autoxidation and reactive oxygen species play little, if any role in mediating lipid oxidation *in vivo* (17-19).

Further studies disclosed herein have more fully revealed and likewise confirmed the significance of the findings presented therein. Accordingly, it is toward the presentation of these findings and the further elaboration of the various earlier stated embodiments of the invention that the present disclosure is directed.

#### SUMMARY OF THE INVENTION

In a first aspect of the invention, the *in vivo* oxidation of lipids has been determined to be initiated by the reaction of such lipids to form AGE-lipids as defined herein. Accordingly, the invention extends to a method for modulating the *in vivo* oxidation of lipids by controlling the formation and presence of AGE-lipids. A corresponding diagnostic utility comprises the measurement of the course and extent of *in vivo* lipid oxidation by a measurement of the presence and amount of AGEs and particularly, AGE-lipids as defined herein. An assay is included that may use the AGE-lipids of the present invention to identify disease states characterized by the presence of AGE-lipids. Additionally, such an assay can be utilized to monitor therapy and thus adjust a dosage regimen for a given disease state characterized by the presence of AGE-lipids.

More particularly, as the *in vivo* oxidation of lipids is related to the onset and course of atherosclerosis, the control of *in vivo* lipid oxidation represents a  
5 therapeutic strategy for its treatment, and the invention thus comprises a method for treating atherosclerosis by inhibiting the formation of AGE-lipids. Likewise, the measurement of AGE-lipid levels in mammals represents a method for diagnosing the likelihood or onset of  
10 atherosclerosis, or measuring the course or severity of the disease.

As noted above, AGE-lipids are useful as markers of a variety of conditions in which the fluctuation in lipid  
15 levels may reflect the presence or onset of dysfunction or pathology. AGE-lipids are also lipid-soluble and are useful alone and in conjunction with known carriers and delivery vehicles, such as liposomes, for the transport of therapeutic and other agents, including in certain  
20 instances the AGE moieties themselves, across membranes and epithelial layers, for example, to particular sites in a patient for treatment. The particular site of interest may be one which has at least one AGE receptor which recognizes the AGE-lipid or a portion thereof.

25 A method of preparing AGE-lipids is also disclosed which comprises incubating the lipid with an advanced glycosylation endproduct or a compound which forms advanced glycosylation endproducts for a length of time  
30 sufficient to form said AGE-lipid.

Pharmaceutical compositions are also disclosed that comprise an AGE-lipid in combination with a pharmaceutically acceptable carrier. Such pharmaceutical  
35 compositions may include an additional active agent(s) in some instances, and may be prepared and used for oral, parenteral or topical, e.g., transdermal, sublingual,

buccal or transmucosal delivery. As stated, the pharmaceutical compositions can be in the form of a liposome in certain instances.

5 Further, AGE-lipids also demonstrate therapeutic utility and may accordingly be prepared as described above, for administration in controlled quantities to stimulate the uptake and removal of senescent macromolecules, to promote skin rejuvenation or remodeling by such activity, and to serve as a drug delivery means. In this connection, the AGE-lipids and pharmaceutical compositions containing them may be prepared and administered as and where appropriate.

15 A further embodiment of the invention relates to the concomitant discovery that the *in vivo* oxidation of LDL is likewise initiated by the formation of LDL advanced glycosylation endproducts (AGE-LDL). AGE-LDL may be formed by reaction with glucose or another *in vivo*-resident reducing sugar, an advanced glycosylation endproduct, or active fragments thereof, including AGE peptides circulating in the serum of a mammal. More particularly, the formation of AGE-LDL comprises the attachment of AGE moieties to either or both the lipid and apoprotein components, in the latter instance to form AGE-apo B.

Apo B, in turn, has a region within its receptor binding domain that is susceptible to AGE modification. This site may be protected from AGE modification as part of a therapeutic strategy, and may also serve as the focal point of a drug discovery assay or receptor assay in a diagnostic context.

35 Accordingly, the invention includes a method for diagnosing or monitoring conditions in which serum LDL or cholesterol levels are abnormal comprising measuring the

presence and amount of a marker selected from AGE-lipids, AGE-LDL and AGE-apo B. The stated method may be used for example, to diagnose or monitor atherosclerosis and diabetes. A corresponding therapeutic method comprises  
5 the treatment of a mammal to modulate, and in the majority of instances, to lower serum LDL or cholesterol levels, by the administration of an agent that serves to modulate AGE-LDL levels, and specifically to inhibit the formation of AGE-LDL.

10

Also, a method of modulating lipid metabolism in a mammal in need of such treatment is included. The method comprises administering to said mammal a lipid  
metabolism-modulating effective amount of an agent that  
15 can modify the recognition and removal of lipids from serum, and more particularly, such agents as can modify the recognition and binding of apo B by LDL receptors.

Generally, the therapeutic methods of the present  
20 invention contemplate the inhibition of *in vivo* lipid oxidation, LDL level increases or apo B modifications, by the administration of an agent or a pharmaceutical composition containing such agent or a plurality of such agents, for the inhibition of the formation of advanced  
25 glycosylation endproducts involving any or all of the lipid and lipid-related materials subject to such *in vivo* oxidation. Such agents comprise antagonists of advanced glycosylation, and include antibodies to AGEs, antibodies to AGE-lipids, antibodies to AGE-LDL, antibodies to AGE-  
30 apo B, as well as other ligands that would bind and neutralize the foregoing antigens. Suitable agents may also be selected from those agents that are reactive with an active carbonyl moiety on an early glycosylation product, and preferably are selected from aminoguanidine,  
35  $\alpha$ -hydrazinohistidine, analogs of aminoguanidine, and pharmaceutical compositions containing any of the foregoing, all as recited in detail herein. The

inventions set forth herein contemplate the discovery of additional agents that may then be used in like fashion and for like purpose.

- 5 In an alternate embodiment, the *in vivo* oxidation of lipids, once initiated, is driven by the presence and activity of the lipid peroxidation breakdown products. These include lipid peroxides, as well as highly reactive aldehydes such as malonyl dialdehyde (MDA). These  
10 aldehydes can react with and/or crosslink to proteins, for example, through available free amino groups. Inhibitors of AGE formation such as aminoguanidine may be used to inhibit the activity of these reactive aldehydes by reacting directly with them. Accordingly, a  
15 therapeutic strategy for the treatment of atherosclerosis or other conditions in which LDL levels, cholesterol levels or lipid levels generally, are undesirably high comprises the administration of a therapeutically effective amount of an agent capable of neutralizing the  
20 activity of the reactive aldehyde products of *in vivo* lipid oxidation. Preferred inhibitors include the agents and antagonists recited above, and other materials disclosed herein.
- 25 Accordingly, it is a principal object of the present invention to modulate and control the *in vivo* oxidation of lipids and lipid-like moieties by controlling the formation of advanced glycosylation endproducts (AGEs), and particularly AGEs involving such lipid and lipid-like  
30 moieties.

It is a further object of the present invention to provide a method for diagnosing conditions in which abnormal lipid oxidation is a characteristic, by  
35 detecting and measuring the presence and extent of lipid-AGE formation.

It is a still further object of the present invention to provide a method for diagnosing and treating atherosclerosis by measuring and inhibiting the formation of AGE-lipids.

5

It is a still further object of the present invention to provide a method for lowering serum LDL levels, by inhibiting the formation of AGEs including AGE-lipids.

10 It is a still further object of the present invention to provide a method for identifying new drugs and corresponding agents capable of treating abnormal lipid oxidation, by use of an assay involving AGE-lipids.

15 It is yet another object is to utilize AGE-lipids to treat certain diseases and conditions, such as skin conditions, or to utilize the AGE-lipid moieties for purposes of delivering disease-treating medications to particular biologically active sites.

20

It is a still further object of the present invention to identify AGE-lipids and methods of inhibiting the formation in instances or disease conditions where the presence or biological activity of these AGE-lipids is  
25 detrimental to the host organism, or indicative of the presence of a disease state in the host organism.

Other objects and advantages will be apparent from a consideration of the ensuing detailed description which  
30 proceeds with reference to the following illustrative drawings.

#### BRIEF DESCRIPTION OF THE DRAWINGS

35 FIGURE 1 is a graph of absorbance at 360 nm of AGE-compound formation over time using various lipids incubated with glucose and/or aminoguanidine;

FIGURE 2 is a graph of fluorescence intensity using various lipids incubated with glucose and/or aminoguanidine;

- 5 FIGURE 3 is a graph of lipid oxidation in relation to AGE-lipid formation using various lipids incubated with glucose and/or aminoguanidine;

- 10 FIGURE 4 is a graph of changes in ultraviolet and visible absorbance spectra (200-500 nm) over time (0-50 days) of phosphatidylethanolamine (PE) incubated with 500 mM glucose;

- 15 FIGURE 5 is a graph of AGE-specific absorbance as a function of glucose concentration;

FIGURE 6 is a graph of AGE-specific fluorescence as a function of glucose concentration;

- 20 FIGURE 7 is a graph of lipid oxidation changes as a function of glucose concentration;

- FIGURE 8A is a graph showing the concentration-dependent reaction between malonyldialdehyde (bis-[diethylacetal]) (MDA) (0-20  $\mu$ M) and aminoguanidine (0-500  $\mu$ m);
- 25

FIGURE 8B is a graph of the inhibition of thiobarbiturate activity as a function of AG concentration.

30

- FIGURES 9A-C are graphs of the comparison measurement of AGE and oxidative modification of human LDL isolated from plasma of 8 normoglycemic, non-diabetic individuals (o) and 16 patients with diabetic mellitus: FIGURE 9A compares the AGE modification of LDL apoprotein of non-diabetic and diabetic patients. FIGURE 9B compares the AGE modification of LDL lipid of non-diabetic and
- 35

diabetic patients; and FIGURE 9C compares the oxidative modification of LDL of non-diabetic and diabetic patients. Values shown are the mean of duplicate determinations.

5

FIGURES 10A-C are graphs of time-dependent reaction of human LDL (2.5 mg/ml) with glucose (200 mM). At time intervals, samples were dialyzed against PBS/EDTA and portions separated into lipid (FIGURE 10B) and apoprotein (FIGURE 10A) components for AGE determination or assayed for the presence of ox-LDL (FIGURE 10C). LDL incubated with 200 mM glucose ( $\Delta$ ). LDL incubated with 200 mM glucose and 300 mM aminoguanidine ( $\Delta$ ). LDL incubated alone (o). LDL incubated with aminoguanidine ( $\bullet$ ).  
15 Values shown are the mean of duplicate determinations.

FIGURE 11A presents histograms depicting the accumulation of AGEs on apo B that was isolated after incubation of LDL with AGE-peptides, with or without co-incubation with aminoguanidine, as detected in an AGE-specific ELISA.  
20

FIGURE 11B presents histograms depicting the accumulation of AGEs in a lipid fraction that was isolated after incubation of LDL with AGE-peptides, with or without co-incubation with aminoguanidine, as detected in an AGE-specific ELISA.  
25

FIGURE 12A presents histograms depicting the accumulation of AGEs (as detected in an AGE-specific ELISA) on apo B that was isolated from serum LDL obtained from human study subjects who were non-diabetic (normal) or diabetic with different numbers of diabetic complications, and diabetic patients with end stage renal disease (ESRD).  
30

FIGURE 12B presents histograms depicting the accumulation of AGEs (as detected in an AGE-specific ELISA) in a lipid fraction that was isolated from LDL obtained from human  
35

study subjects who were non-diabetic (normal) or diabetic with different numbers of diabetic complications, and diabetic patients with end stage renal disease (ESRD).

5 FIGURE 12C presents histograms depicting the accumulation of oxidized LDL (detected as MDA equivalents) in plasma LDL that was obtained from human study subjects who were non-diabetic (normal) or diabetic with different numbers of diabetic complications, and diabetic patients with end  
10 stage renal disease (ESRD).

FIGURE 13 presents histograms depicting the accumulation of AGEs (as detected in an AGE-specific ELISA) on apo B that was isolated from plasma LDL obtained from human  
15 study subjects who were non-diabetic (normal) or diabetic and with or without end stage renal disease.

FIGURE 14 presents histograms depicting the relative lowering of LDL levels (shown as percent of pretreatment  
20 baseline) in diabetic patients at the end of a 28-day trial of aminoguanidine versus placebo.

#### DETAILED DESCRIPTION OF THE INVENTION

25 Numerous abbreviations are used herein to simplify the terminology used, and to facilitate a better understanding of the invention. The following abbreviations are representative.

30 As used herein, the term "AGE-" refers to the compound which it modifies as the reaction product of either an advanced glycosylation endproduct or a compound which forms AGEs and the compound so modified, such as the lipid moiety. AGE-lipids can be formed *in vitro* by  
35 reacting a lipid as defined herein with an AGE, such as AGE-peptide, or either *in vitro* or *in vivo* with a

compound such as a reducing sugar, e.g., glucose, until the lipid is modified to form the AGE-lipid.

"Lipid" is used in the conventional sense to refer to materials that are soluble to a greater or lesser degree in organic solvents, like alcohols, and relatively insoluble in aqueous media. Thus, the term "lipid" includes compounds of varying chain length, from as short as about 2 carbon atoms to as long as about 28 carbon atoms. Additionally, the compounds may be saturated or unsaturated, and in the form of straight- or branched-chains or in the form of unfused or fused ring structures. Further, these lipid compounds can be optionally linked to other moieties, so long as at least one primary amino group, or other crosslinkable or otherwise reactive group, is present in the molecule.

The term "lipid-related materials" is used herein to encompass not only lipids as conventionally understood and as defined above, but those particles, aggregates and components thereof that are found in connection with lipid moieties. Examples of lipid-related materials included herein include fatty acids, sterol-type molecules, triglycerides, phospholipids, and lipoproteins including apolipoproteins. Preferred lipid-related materials include as the AGE-reactive groups one or more primary amino groups. It is particularly preferred to include at least one primary amino group reactive with AGEs and compounds which form AGEs.

The lipid-related materials that are of primary interest are those that react to form advanced glycosylation endproducts. The resulting AGEs are given herein the common designation of "AGE-lipid(s)" for purpose of convenience and consistency, it being understood that this designation will include within its scope AGEs formed literally with lipid moieties alone, as well as

AGES formed with lipid-related materials such as apolipoproteins. The use of the term "AGE-lipid(s)" in accordance with the present invention is therefore intended to cover such diverse materials within its  
5 scope.

Those lipid-related materials that are preferably used in the preparation of the AGE-lipids affirmatively used in the diagnostic and therapeutic methods of the present  
10 invention, are phospholipid compounds containing primary amino groups, such as phosphatidylethanolamine. Other lipid-related materials also useful in the present invention are the lipoproteins, particularly those involved in atherogenesis, i.e., low-density lipoproteins  
15 (LDLs), and the apolipoproteins that comprise the protein component of LDL, and in particular, apolipoprotein B (apo B).

The AGEs that may be employed to prepare AGE-lipids  
20 include such species as 2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazole ("FFI"); 5-hydroxymethyl-1-alkylpyrrole-2-carbaldehyde ("Pyrraline"); 1-alkyl-2-formyl-3,4-diglycosyl pyrrole ("AFGP"), a non-fluorescent model AGE; carboxymethyllysine; and pentosidine. These compounds  
25 have been isolated and characterized as the reaction products which form following the formation of Amadori reactions. However, the *in vivo* formation of AGEs and the incubation of lipids with AGEs or compounds which form AGEs likely forms AGE species not recited above.  
30 Consequently, the invention is not limited to these precise chemical compounds, since other AGE compounds can be formed or have a role in accordance with the teachings herein. Thus, the term AGE can refer to the advanced glycosylation endproduct which the lipid is reacted with  
35 as well as the particular form which is produced according to the reaction.

As stated earlier, the present invention is related in part to the discovery that a relationship exists between lipid oxidation and metabolism, and the *in vivo* formation of advanced glycosylation endproducts on lipid-related materials as defined hereinabove (AGE-lipids).

Particularly, and as supported by the data presented herein, AGE-lipids appear to initiate lipid oxidation, reduce the efficiency and operation of the body mechanism for LDL clearance by the interruption of normal receptor binding between the apolipoprotein B portion of LDL and appropriate LDL receptors, and leads to increased levels of plasma lipids such as low density lipoproteins (LDL).

This latter observation is believed to reflect the existence of a site for the formation of AGEs that is either adjacent or within the LDL receptor binding domain of apo B. The result of the formation of an AGE on apo B is believed to subject apo B to preferential uptake by macrophage "scavenger" receptors with concomitant inhibition of interaction with the LDL receptor, with the result that the LDL molecules are avidly consumed by the macrophage leading to the formation of undesired foam cells that contribute to atherosclerotic plaque formation. It is therefore of primary interest and importance as a therapeutic strategy, to treat atherosclerosis in more than one way, first by the inhibition of AGE formation and lipid oxidation that, in turn, leads to increased plasma LDL levels, and secondly, to restore the full functionality of apo B uptake by LDL receptors and to avert the formation of undesired foam cells by the consumption of LDL by the macrophage.

A further discovery in accordance with the present invention that forms yet an additional aspect thereof, is the observation that the oxidation of lipids, while initiated by AGE-lipid formation, is further perpetuated by the circulation of certain lipid oxidation byproducts.

Also, fatty acid oxidation products such as the malonyl dialdehyde-like compounds participate in protein modification by reaction with free available amino groups. It therefore is desirable as a further  
5 therapeutic strategy to neutralize the activity of these oxidation byproducts by a reaction of an appropriate neutralizing agent therewith.

As part of the present invention, the inhibitors of  
10 advanced glycosylation identified earlier and listed herein in detail, including aminoguanidine,  $\alpha$ -hydrazinohistidine, lysine and corresponding analogs, have been found and confirmed to react in such fashion with the MDA-like byproducts that are produced *in vivo*  
15 and to neutralize the same so that they no longer participate in the modification of proteins. The present invention is not considered to be limited or to depend upon a particular mechanism of action, and the foregoing is merely illustrative of the observed beneficial  
20 activity of the noted inhibitors.

In view of the above, the present invention includes a dual therapeutic strategy where agents such as aminoguanidine may be administered to inhibit *in vivo*  
25 AGE-lipid formation and consequent initiation of lipid oxidation, and to react with any byproducts of an ongoing lipid oxidation to prevent reaction of these byproducts with proteins as described above.

30 More particularly, the present invention relates to a method of modulating lipid metabolism including the control and adjustment of such metabolism either to increase or decrease same, by the administration to a mammal or host in need of such treatment, of a lipid  
35 metabolism-modulating effective amount of a particular agent or group of agents that are capable of modifying the recognition and removal of lipids from serum, which

agents are importantly capable of controlling the formation of AGEs, and particularly AGE-lipids. In selected instances, such as where predetermined quantities of AGE-lipids may act to stimulate the systems of the host to adjust lipid metabolism for therapeutic benefit, the method includes the administration of such AGE-lipids by means described herein in detail.

The lipids subject to advanced glycosylation are as recited earlier, selected from amine-containing lipids, low-density lipoproteins, and apolipoproteins, and particularly in the last mentioned instance, apo B. The method may be practiced to lower low-density lipoprotein levels in a patient, and is applicable for example, to the prevention and/or treatment of hypercholesterolemia, atherosclerosis, and kidney failure.

The agents contemplated for use in this method include materials selected from the group consisting of antibodies against advanced glycosylation endproducts, ligands, including AGE receptors and active fragments thereof, capable of binding to and neutralizing advanced glycosylation endproducts, and compounds capable of inhibiting the formation of advanced glycosylation endproducts. Suitable antibodies include polyclonal antibodies, monoclonal antibodies, chimeric antibodies, and active fragments thereof, all as discussed in detail below. These agents are administered to restore effective lipid metabolism and to correspondingly reduce lipid oxidation. The foregoing appreciates that lipid metabolism is in part controlled by the effective binding of the apolipoprotein apo B to the LDL receptor, so that any compounds or agents contemplated for use in this aspect of the invention, would be capable of interacting with the receptor binding domain of apo B to avert the formation of AGEs adjacent to or therewithin, and to

render such receptor binding domain recognizable by the LDL receptor.

As mentioned previously and as supported by one of the  
5 examples presented later on herein, it has been observed  
that such AGE-peptides take an affirmative role in the  
formation of AGE-lipids and likewise participate in the  
promotion and acceleration of lipid oxidation and the  
various consequences thereof. It is therefore desirable,  
10 in the instance where such activity is to be inhibited,  
to neutralize such AGE-peptides by reacting with them to  
prevent them from promoting further AGE formation. In  
this connection, aminoguanidine and like inhibitor  
compounds can be administered.

15

Concomitant with the above therapeutic strategies are  
effective diagnostic protocols that may be employed to  
determine the onset and course of a condition whose  
measurable variable may include lipid oxidation, by  
20 resort to the detection and measurement of the extent of  
advanced glycosylation of lipids. More particularly,  
AGE-lipid formation may be detected by means such as the  
AGE-ELISA developed by the present inventors, to  
determine the extent of AGE-lipid formation and to  
25 thereby assess the extent of lipid oxidation, and  
consequent effects on plasma LDL levels. Accordingly,  
measurable increases in lipid oxidation and plasma LDL  
levels will signal the development and onset of  
hypercholesterolemia and atherogenesis, so that the  
30 present method may be effectively employed to diagnose  
and monitor the development of vascular disease, and  
particularly atherosclerosis. Likewise, the presence of  
AGE-lipids is also reflective of the development and  
existence of diabetic conditions such as diabetic  
35 retinopathy, diabetic and non-diabetic nephropathy, and  
the like, so that the present diagnostic methods may be

used to measure the development and severity of these conditions as well.

With respect to the effect that advanced glycosylation  
5 endproduct formation exerts on the ability to clear low  
density lipoproteins by the recognition and binding of  
apo B to the LDL receptor, the present invention  
contemplates and includes the full identification of the  
receptor binding domain of apo B, and particularly those  
10 portions of the receptor binding domain that are  
presently susceptible to AGE formation. For example, and  
as set forth later on herein, Applicants have discovered  
that a particular segment of the receptor binding domain  
defines lysine with flanking arginine residues, that most  
15 likely serves as a site for the formation of the advanced  
glycosylation endproduct with apo B.

Accordingly, the receptor binding domain may serve as the  
focal point for a drug discovery assay, where, for  
20 example, apo B may be immobilized, and incubated both  
with agents conducive to the formation of an AGE on the  
binding domain thereof, and a quantity of a particular  
drug or inhibitory agent under test. The extent to which  
the drug serves to either bind with the AGE and thereby  
25 inhibit apo B AGE formation, or binds directly with apo B  
and thereby prevents the same, could then be measured.  
This particular assay could be prepared as a receptor  
assay in conjunction with the LDL receptor, to determine  
whether the apo B receptor binding domain is disabled  
30 after incubation with an AGE/AGE-forming materials and a  
particular drug under test. Both possibilities for drug  
discovery assays are contemplated herein and are  
considered within the scope of the present invention.

35 Both the diagnostic and therapeutic methods of the  
present invention contemplate the use of agents that have  
an impact on the formation of AGE-lipids. Among these

agents, antibodies to AGEs and other ligands may be prepared and used. These terms are defined below.

The term "antibody" includes any immunoglobulin, including antibodies and fragments thereof that binds a specific epitope, and such general definition is intended to apply herein. The term therefore encompasses polyclonal, monoclonal and chimeric antibodies, the last mentioned described in further detail in U.S. Patent Nos. 4,816,397 and 4,816,567.

Also, an "antibody combining site" is that structural portion of an antibody molecule comprised of heavy and light chain variable and hypervariable regions that specifically bind antigen. Exemplary antibodies include antibody molecules such as intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contain the active binding site, including those portions known in the art as Fab, Fab', F(ab')<sub>2</sub>, and F(v), which portions are preferred for use in therapeutic methods associated herein.

Fab and F(ab')<sub>2</sub> portions of antibody molecules are prepared by the proteolytic reaction of papain and pepsin, respectively, on substantially intact antibody molecules by methods that are well-known. See for example, U.S. Patent No. 4,342,566 to Theofilopolous et al. (The disclosures of the art cited herein are hereby incorporated by reference.) Fab' antibody molecule portions are also well-known and are produced from F(ab')<sub>2</sub> portions followed by reduction of the disulfide bonds linking the two heavy chain portions as with mercaptoethanol, and followed by alkylation of the resulting protein mercaptan with a reagent such as iodoacetamide.

The phrase "monoclonal antibody" in its various grammatical forms refers to an antibody having only one species of antibody combining site capable of immunoreacting with a particular antigen. A monoclonal antibody thus typically displays a single binding affinity for any antigen with which it immunoreacts. An antibody may be prepared having a plurality of antibody combining sites, each immunospecific for a different antigen; e.g., a bispecific (chimeric) antibody.

Likewise, the term "ligands" includes such materials as AGE derivatives that would bind to AGE-binding partners, and would include such materials as are prepared by the reaction of AGEs with avidin or biotin, or the preparation of synthetic AGE derivatives that may be prepared from reducing sugars such as glucose, glucose-6-phosphate (G-6-P), fructose and ribose, and peptides, proteins and other biochemicals such as bovine serum albumin (BSA), avidin, biotin derivatives, and enzymes such as alkaline phosphatase. Likewise, enzymes and other carriers that have undergone advanced glycosylation may also serve as ligands in any of the assays of the present invention. Accordingly, carriers such as carbohydrates, proteins, synthetic polypeptides, lipids and biocompatible natural and synthetic resins, and any mixtures of the same may be reacted with sugars to form advanced glycosylation endproducts and may thereby be useful in the present methods. The present diagnostic methods are intended to contemplate all of the foregoing materials within their scope.

The term "AGE binding partners" is intended to extend to anti-AGE antibodies and to other cellular AGE binding proteins or receptors for AGEs, which AGEs may be found on peptides, molecules and cells.

As discussed above, the present invention extends to the preparation and use of AGE-lipids in a variety of diagnostic and therapeutic contexts. With respect to the formation of AGE-lipids, the compounds which form AGEs  
5 are typically reducing sugars. Reducing sugars or the AGEs themselves can react with the lipids to form AGE-lipids. However, in in vitro techniques, it is likely that a compound which forms AGEs, such as a reducing sugar, will be used. Examples of reducing sugars include  
10 glucose, fructose, ribose and glucose-6-phosphate.

AGE-lipids can be affirmatively used in the treatment, rejuvenation or remodeling of skin. For example, the AGE-lipids can be administered in an amount effective for  
15 treating skin ailments or rejuvenating or remodeling the skin, such as to remove or induce the removal of wrinkles. By way of explanation, but not limitation, it is postulated that the application of AGE-lipids to the skin may attract cells, e.g., macrophages, which have the  
20 ability to remove naturally occurring AGE-compounds generally from the site of deposition. As a result, in vivo generated and naturally deposited AGE-compounds may be removed and also AGE-lipids and other AGEs may induce cells, e.g., macrophage, T-cells and endothelial cells  
25 and fibroblasts, to secrete a variety of substances, e.g., cytokines, growth factors and effector molecules, such as TNF, IL-1, IGF-1, PDGF and other compounds, and collagenase and thereby modulate biological processes, e.g. skin remodeling and wound healing.

30

The AGE-lipids can be applied to the skin in the form of topical preparations for cosmetic or medicinal use in the form of, e.g., creams, gels or ointments, or can be incorporated into pharmaceutical preparations with other  
35 ingredients. Likewise, the topical use of the AGE-lipid compounds described herein could include other agents

useful for the treatment of skin ailments or disease, e.g., wrinkling, acne, wound healing, etc.

The AGE-lipids of the present invention can also be  
5 applied to the skin to modify the effect or use of other medicinal agents. For example, the AGE-lipids could be applied to the skin in conjunction with anti-inflammatory or anti-infective therapeutic agents or other compounds which are effective topically or transdermally.  
10 Likewise, such AGE-lipids may enhance the penetration or activity of the other compounds administered in combination.

Additionally, the AGE-lipids may function to attract  
15 cells or other endogenous components, e.g., antibodies, which are effective in removing AGEs from the system, or which function in the removal of such compounds from the system. By providing AGE-lipids to the desired site, these cells and other components may be attracted to the  
20 area of application and induced to remove other harmful components.

Another aspect of the present invention relates to compositions which can be in any pharmaceutically  
25 acceptable form, e.g., transdermal, oral, parenteral, topical (via the skin, inhalation, transmucosally, e.g., rectally, vaginally, buccally or sublingually) as well as other dosage forms administered by other routes of administration. Such compositions typically contain an  
30 AGE-lipid which is effective for treating the particular disease or condition, or is effective for attracting, activating or inducing the activity of cells or antibodies to the area of interest in an effort to control, reduce or eliminate the formation of lipofuscin,  
35 and other amyloid materials. The amount of the AGE-lipid present in the composition and thus the amount administered will depend upon the particular condition

under treatment, as well as the age, weight, and condition of the patient.

Also, the AGE-lipids of the present invention may be  
5 useful for the enhancement of the activity of other drugs  
or therapeutic agents. For example, the AGE-lipid can be  
coadministered or administered separately from another  
drug to take advantage of the lipid solubility of the  
preferred AGE-lipids which are useful herein. Likewise,  
10 the drugs can be used essentially simultaneously to  
attract cells or other biological components, e.g.,  
antibodies, which are to be treated or are necessary or  
desired in the pharmacological site of activity for  
purposes of enhancing the activity of the AGE-lipid  
15 and/or the other drug.

Another aspect of the invention relates to pharmaceutical  
dosage forms such as liposomes. Liposomes can be used  
with AGE-lipids present on the outer layer thereof, or  
20 incorporated into the interior, based upon the lipid  
solubility of the AGE-lipid, the relative size of the  
liposomes, the presence of other therapeutic agents  
contained therein, the mode and biological site of  
intended use/activity and numerous other factors.

25

Preferred AGE-lipids for use as described herein may take  
advantage of cellular AGE binding proteins or AGE-  
receptors as well as the other physical parameters of the  
AGE-lipids described in the present invention. By way of  
30 non-limiting example, the synthetic and naturally  
occurring AGE, FFI, is recognized by and reactive with  
macrophage cells (macrophage cells have AGE receptors  
which recognize FFI) but not particularly reactive with  
endothelial cells. Thus, if a liposome or other  
35 pharmaceutical dosage form containing AGE-lipids is to be  
delivered such that macrophage cells are targeted, the  
FFI moiety can be included. In this manner, differences

in AGE receptor activity and in the reactivity of different AGEs can be taken advantage of.

Likewise, the AGE-lipids of the present invention can be used to produce antibodies to AGE-lipids, and these antibodies can be used as described herein. For example, antibody formation can be induced by injecting a mammal with an immunogen comprised of an AGE-lipid and then collecting the serum of the mammal. Such serum will typically contain antibodies which recognize and bind to AGE-lipids. These antibodies may be polyclonal or essentially monoclonal, and may be prepared e.g., by using an appropriate immunization protocol, such as a hyperimmunization protocol. Accordingly, appropriate fusion, plating, screening, selection and replication techniques can be utilized to obtain monoclonal antibodies which recognize specific epitopes on the particular AGE-lipid utilized.

The AGE-lipids, antibodies and compositions can also be used in the assessment of the quality, preservation or degradation of stored foods or other biological substances. For example, the presence and concentration of advanced glycosylation endproducts can be identified. This technique is particularly useful in identifying undesirable concentrations of advanced glycosylation endproducts that accumulate with prolonged storage.

The AGE-lipids, antibodies and compositions can be used in the diagnosis and assessment of certain diseases. For example, the location and concentrations of advanced glycosylation endproducts in the body could be identified. This technique is particularly useful in identifying undesirable concentrations of advanced glycosylation endproducts, such as atheromatous plaques, or for the identification of complications of disease states such as diabetes mellitus.

Of particular diagnostic importance is the identification of AGE-lipids wherein the lipid is a low-density lipoprotein (LDL). In the case of LDL, incubation with glucose or AGE-peptides produces AGE moieties that are  
5 linked to both the lipid and to the apoprotein components. Oxidized-LDL forms concurrently with AGEs during these incubations. Aminoguanidine, as well as other known agents for the inhibition of the advanced glycosylation of proteins, inhibits both the advanced  
10 glycosylation and oxidative modification processes. Analysis of LDL specimens isolated from the plasma of diabetic individuals reveals increased levels of AGEs on both the apoprotein and lipid components when compared to normal, non-diabetic individuals. The level of LDL,  
15 oxidation also correlates significantly with AGE modification, indicating that advanced glycosylation may play a primary role in the generation of oxidized lipid *in vivo*, and that this activity is inhibited by aminoguanidine.

20 Thus, the identification, by standard assay procedures, of high levels of AGE-LDL in a patient can be utilized to ascertain the precise disease state, as well as to monitor the efficacy of a therapeutic regimen, such as by  
25 treatment with an AGE-inhibitor. In a particularly preferred embodiment, the levels of AGE-LDL in a patient can be utilized to diagnose the onset, severity or risk for the development of diabetic conditions and complications in the patient. Additionally, the level of  
30 AGE-LDL in a patient can be utilized to diagnose the onset or severity of atherosclerosis and associated conditions in a patient.

The method comprises an assay involving in addition to  
35 the analyte, one or more binding partners of AGE-lipids and one or more ligands.

Accordingly, the present assay method broadly comprises the steps of:

- A. preparing at least one biological sample suspected of containing said AGE-lipids;
- 5 B. preparing at least one corresponding binding partner directed to said sample;
- C. placing a detectable label on a material selected from the group consisting of said sample, a ligand to said binding partner and said binding partner;
- 10 D. placing the labeled material from Step C in contact with a material selected from the group consisting of the material from Step C that is not labeled; and
- E. examining the resulting sample for the  
15 extent of binding of said labeled material to said unlabeled material.

In a typical non-competitive assay in accordance with the present invention, AGE-lipids are solubilized in methanol  
20 and deposited on the assay plate by drying. The assay plates are then hydrated and sequentially exposed to anti-AGE primary antibodies and enzyme-conjugated second antibodies specific for the primary antibodies, with washing steps in between where appropriate. Enzyme  
25 levels are then determined by, for instance, substrate conversion protocols well known in the art, and the amount of AGEs can thus be measured by reference to a standard run in parallel.

30 In a typical competitive assay in accordance with the present invention, an AGE binding protein or AGE receptor may be combined with the analyte and a ligand, and the binding activity of either or both the ligand or the analyte to the receptor may then be measured to determine  
35 the extent and presence of the advanced glycosylation endproduct of interest. In this way, the differences in

amounts bound between the components of the assay serves to identify the presence and amount of the AGE-lipid.

The present invention also relates to a method for  
5 detecting the presence of stimulated, spontaneous, or  
idiopathic pathological states in mammals, by measuring  
the corresponding presence of AGE-lipids. More  
particularly, the activity of AGEs may be followed  
directly by assay techniques such as those discussed  
10 herein, through the use of an appropriately labeled  
quantity of at least one of the binding partners to AGE-  
lipids as set forth herein. Alternately, AGEs can be  
used to raise binding partners or antagonists that could  
in turn, be labeled and introduced into a medium to test  
15 for the presence and amount of AGEs therein, and to  
thereby assess the state of the host from which the  
medium was drawn.

Thus, both AGE-lipids and any binding partners thereto  
20 that may be prepared, are capable of use in connection  
with various diagnostic techniques, including  
immunoassays, such as a radioimmunoassay, using for  
example, a receptor or other ligand to an AGE that may  
either be unlabeled or if labeled, then by either  
25 radioactive addition, reduction with sodium borotritide,  
or radioiodination.

In an immunoassay, a control quantity of a binding  
partner to AGE-lipids may be prepared and optionally  
30 labeled, such as with an enzyme, a compound that  
fluoresces and/or a radioactive element, and may then be  
introduced into a tissue or fluid sample of a mammal.  
After the labeled material or its binding partner(s) has  
had an opportunity to react with sites within the sample,  
35 the resulting mass may be examined by known techniques,  
which may vary with the nature of the label attached.

The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to ultraviolet light, and others.

- 5 Suitable examples of radioactive elements include  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{36}\text{Cl}$ ,  $^{51}\text{Cr}$ ,  $^{57}\text{Co}$ ,  $^{58}\text{Co}$ ,  $^{59}\text{Fe}$ ,  $^{90}\text{Y}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ , and  $^{186}\text{Re}$ .

In the instance where a radioactive label, such is prepared with one of the above isotopes is used, known currently available counting procedures may be utilized.

10

In the instance where the label is an enzyme, detection may be accomplished by any of the presently utilized colorimetric, spectrophotometric, fluorospectro-

- 15 techniques known in the art. The enzyme may be conjugated to the advanced glycosylation endproducts, their binding partners or carrier molecules by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like.

20

Many enzymes which can be used in these procedures are known and can be utilized. The preferred are peroxidase,  $\beta$ -glucuronidase,  $\beta$ -D-glucosidase,  $\beta$ -D-galactosidase, urease, glucose oxidase plus peroxidase, hexokinase plus

- 25 GPDase, RNase, glucose oxidase plus alkaline phosphatase, NAD oxidoreductase plus luciferase, phosphofructokinase plus phosphoenol pyruvate carboxylase, aspartate aminotransferase plus phosphoenol pyruvate decarboxylase, and alkaline phosphatase. U.S. Patent Nos. 3,654,090;  
30 3,850,752; and 4,016,043 are referred to by way of example for their disclosure of alternative labeling material and methods. A particular enzymatic detecting material is anti-rabbit antibody prepared in goats and conjugated with alkaline phosphatase through an  
35 isothiocyanate.

A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine and auramine. A particular fluorescent detecting material is anti-rabbit antibody  
5 prepared in goats and conjugated with fluorescein through an isothiocyanate.

The AGE-lipids may be used to produce antibody(ies) to themselves which can be produced and isolated by standard  
10 methods including the well known hybridoma techniques. The antibody(ies) can be used in another species as through they were antigen(s) to raise antibody(ies). Both types of antibody(ies) can be used to determine the amount and location of the AGE-lipids in lipid masses,  
15 whether in foodstuffs, or in the mammalian body. For convenience, the antibody(ies) to the AGE-lipids will be referred to herein as Ab<sub>1</sub> and antibody(ies) raised in another species as Ab<sub>2</sub>.

20 The degree of glycosylation in lipid masses suspected of undergoing the same can be ascertained by the usual immunological procedures applicable to such determinations. A number of useful procedures are known. Three such procedures which are especially useful utilize  
25 either the AGE-lipid labeled with a detectable label, antibody Ab<sub>1</sub> labeled with a detectable label, or antibody Ab<sub>2</sub> labeled with a detectable label. The procedures may be summarized by the following equations wherein the asterisk indicates that the particle is labeled, and "Al"  
30 stands for the AGE-lipid:

A.  $Al^* + Ab_1 = Al^*Ab_1$

B.  $Al + Ab_1^* = AlAb_1^*$

C.  $Al + Ab_1 + Ab_2^* = AlAb_1Ab_2^*$

35

The procedures and their application are all familiar to those skilled in the art and accordingly may be utilized

within the scope of the present invention. The "competitive" procedure, Procedure A, is described in U.S. Pat. Nos. 3,654,090 and 3,850,752. Procedure C, the "sandwich" Procedure, is described in U.S. Patent Nos. RE 31,006 and 4,016,043. Still other procedures are known such as the "Double antibody", or "DASP" procedure.

In each instance, the AGE-lipid substance forms complexes with one or more antibody(ies) or binding partners and one member of the complex is labeled with a detectable label. The fact that a complex has formed and, if desired, the amount thereof, can be determined by known methods applicable to the detection of labels.

It will be seen from the above, that a characteristic property of  $Ab_2$  is that it will react with  $Ab_1$ . This is because  $Ab_1$  raised in one mammalian species has been used in another species as an antigen to raise the antibody  $Ab_2$ . For example,  $Ab_1$  may be raised in rabbits and  $Ab_2$  may be raised in goats using  $Ab_1$  as an antigen.  $Ab_2$  therefore would be anti-rabbit antibody raised in goats.

Accordingly, a test kit may be prepared for the demonstration of AGE-lipids in a sample, whether in food or in animals, comprising:

- (a) a predetermined amount of at least one labeled immunochemically reactive component obtained by the direct or indirect attachment of AGE-lipids or an AGE binding partner to a detectable label;
- (b) other reagents; and
- (c) directions for use of said kit.

More specifically, the diagnostic test kit may comprise:

- (a) a known amount of the AGE-lipid (or a binding partner) generally bound to a solid phase to form a immunosorbent, or in the alternative, bound to a suitable

tag, or plural such components, etc. (or their binding partners) one of each;

(b) if necessary, other reagents; and

(c) directions for use of said test kit.

5

In a further variation, the test kit may be prepared and used for the purposes stated above, which operates according to a predetermined protocol (e.g.

"competitive", "sandwich", "double antibody", etc.), and

10 comprises:

a. a labeled component which has been obtained by coupling a AGE-lipid or a binding partner thereof to a detectable label;

b. one or more additional immunochemical reagents  
15 of which at least one reagent is a binding partner or an immobilized binding partner, which binding partner is selected from the group consisting of:

(i) a binding partner capable of binding with the labeled component (a);

20 (ii) a binding partner capable of binding with a binding partner of the labeled component (a);

(iii) a binding partner capable of binding with at least one of the component(s) to be determined; and

(iv) a binding partner capable of binding with at  
25 least one of the binding partners of at least one of the component(s) to be determined; and

(c) directions for the performance of a protocol for the detection and/or determination of one or more components of an immunochemical reaction between the AGE-  
30 lipid and a specific binding partner thereto.

By example, a solid phase assay system or kit may comprise the solid substrate with either bound binding partner and labeled AGE-lipid or bound AGE-lipid and  
35 labeled binding partner. A sample to be assayed is then placed in contact with the bound and unbound reagent and a competitive reaction between the labeled material and

any unlabeled binding partner(s) in the sample will cause the retention of a dependent quantity of the former on the solid substrate, whereupon it can be precisely quantitatively identified. The foregoing explanation of a particular competitive assay system is presented herein for purposes of illustration only, in fulfillment of the duty to present an enabling disclosure of the invention. It is to be understood that the present invention contemplates a variety of diagnostic protocols within its spirit and scope.

As discussed earlier, the present invention includes potential methods for treating lipids undergoing glycosylation in an effort to retard if not totally inhibit the progress of the Maillard and non-enzymatic glycosylation processes. The method comprises the development of antagonists that when administered to the glycosylating lipid mass, serve by their structure and/or reactivity, to inhibit rather than facilitate the continued glycosylation of the lipid.

For example, the AGE-lipids of this invention can be utilized as adjuvants due to their cross-linking potential with antigens and also as macrophage stimulants to activate the macrophage to effect removal of AGEs. When a lipid-AGE is utilized as an adjuvant it is reacted or cross-linked with an antigen that is "weak". The addition of AGE-lipid to the antigen produces an antigen which produces a strong reaction due to the presence of the AGE-lipid portion, thus increasing the immunogenicity of the original antigen. The invention is not limited to this methodology, but rather encompasses it within its scope.

As noted earlier, phagocytic cells are capable of recognizing and removing abnormal macromolecules by means of receptors on their surfaces which recognize specific

chemical structures and bind them. Once the abnormal macromolecule is recognized in this way, the phagocytic cell may internalize the macromolecule and may then degrade it. In some instances, the phagocytic cell may  
5 in addition secrete enzymes and other factors to help degrade the molecule or particle extracellularly if it cannot be internalized or to produce other cells to participate in such degradation. After the damaged protein is removed, new growth of normal tissue can  
10 ensue, and normal function of the affected area may resume.

Phagocytic cells in the body comprise numerous types of white blood cells. One type of white blood cell, the  
15 monocyte, is produced in the bone marrow, and circulates briefly in the blood and thereafter enters the tissues where it becomes a macrophage.

As discussed earlier, the present invention extends to  
20 the discovery that the phagocytic cells including monocytes and macrophages can be modified by exposure to stimulator compounds that potentiate the capability of these cells with respect to their recognition and affinity for, and capability to degrade advanced  
25 glycosylation end products. In particular, the exposure of these cells to certain stimulator compounds has been found to increase the number of receptors developed on these cells and to thereby increase the capacity and efficiency of these cells with respect to the recognition  
30 and degradation of advanced glycosylation endproducts. The AGE-lipids of the present invention can function as stimulator compounds.

Accordingly, the method of the present invention  
35 generally comprises exposing the animal body to stimulator AGE-lipids, which cause the body, and its phagocytic cells in particular to become activated and to

increase the recognition and removal of target macromolecules that have undergone advanced glycosylation.

- 5 Various methods of treatment and use are applicable herein. One preferred use is for the treatment or removal of proteinaceous or fatty deposits such as amyloids or lipofuscin in a mammal. The AGE-lipid, an antibody to AGE-lipids, or a compound which inhibits the  
10 formation of AGE-lipids is administered to the mammal in need of such treatment in an amount effective to treat, remove or cause the removal of said lipofuscin.

- Another preferred use is for the treatment or prevention  
15 of skin disorders, e.g., wrinkling. The AGE-lipid, an antibody to AGE-lipids, or a compound which inhibits the formation of AGE-lipids can be administered to the mammal in an amount effective for the treatment or prevention of wrinkling. All forms of administration are possible,  
20 with the most preferred route of administration being topical application in a pharmaceutically acceptable dosage form.

- Without limiting the invention to a particular mechanism  
25 of action, the AGE-lipid may act directly, having a positive or negative metabolic effect, or indirectly, such as by affecting the activity of, e.g., cytokines or macrophage cells or immunological mediators, for instance, which in turn may cause the desired therapeutic  
30 effect.


- Also as stated earlier, the invention extends to the discovery that certain compounds that have previously been identified as inhibitors of the advanced  
35 glycosylation of proteins, also inhibit the formation of lipid advanced glycosylation endproducts and, further, react directly with malonyl-dialdehyde-like fatty acid

oxidation products. These inhibitors of advanced glycosylation endproduct formation in proteins are broadly set forth in U.S. Patent No. 4,758,583, the disclosure of which is incorporated herein by reference.

- 5 These compounds include compounds that react with a carbonyl moiety of an early glycosylation product. Representative of such advanced glycosylation inhibitors are aminoguanidine, lysine and  $\alpha$ -hydrazinohistidine.
- 10 In addition to these specific compounds, other agents capable of inhibiting the advanced glycosylation or proteins have likewise been identified and are also utilizable to similarly inhibit the advanced glycosylation of lipids. These agents are set forth in
- 15 U.S. Patent Nos. 4,908,446; 4,983,604; 5,140,048; 5,175,192; 5,114,943; 5,137,916; 5,130,337; 5,100,919; and 5,106,877, the disclosures of which are likewise incorporated herein by reference.
- 20 Accordingly, such compounds include a variety of hydrazine derivatives having, for example, a generic formula as follows:



wherein R is a group of the formula



- and  $R_1$  is hydrogen or a lower alkyl group of 1-6 carbon atoms, a hydroxyethyl group, or together with  $R_2$  or  $R_4$  may be a lower alkylene bridge of 2-4 carbon atoms;  $R_2$  is
- 40 hydrogen, amino, hydroxy, a lower alkyl group of 1-6 carbon atoms, or together with  $R_1$  or  $R_3$  is a lower

alkylene bridge of 2-4 carbon atoms;  $R_2$  may also be an aminoalkylene group of the formula



wherein  $n$  is an integer of 2-7 and  $R_6$  and  $R_7$  are independently a lower alkyl group of 1-6 carbon atoms or together form a part of a cycloalkyl or heterocyclic ring containing from 1 to 2 heteroatoms, of which at least one is nitrogen; and the second of said heteroatoms is selected from the group consisting of nitrogen, oxygen, and sulfur; with the proviso that when the second of said heteroatoms of the heterocyclic ring is nitrogen and forms a piperazine ring; it may be optionally substituted by a substituent that is identical to the portion of the compound on the first nitrogen of the piperazine ring;  $R_3$  is hydrogen, a lower alkyl group of 1-6 carbon atoms, or together with  $R_2$  or  $R_4$  is a lower alkylene bridge of 2-4 carbon atoms;  $R_4$  is hydrogen, a lower alkyl group of 1-6 carbon atoms or together with  $R_1$  or  $R_3$  is a lower alkylene bridge of 2-4 carbon atoms; or an amino group;  $R_5$  is hydrogen, or a lower alkyl group of 1-6 carbon atoms; with the proviso that at least one of  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  or  $R_5$  is other than hydrogen; or  $R$  is an acyl or a lower alkylsulfonyl group of up to 10 carbon atoms and  $R_1$  is hydrogen; and their pharmaceutically acceptable acid addition salts.

30 The lower alkyl and lower alkoxy groups referred to herein contain 1-6 carbon atoms and include methyl, methoxy, ethyl, ethoxy, propyl, propoxy, butyl, butoxy, pentyl, pentyloxy, hexyl, hexyloxy and the corresponding  
35 branched chain isomers thereof.

The acyl portion referred to herein is a residue of lower alkyl, aryl, and heteroaryl carboxylic acids containing

2-10 carbon atoms. They are typified by acetyl, propionyl, butanoyl, valeryl, hexanoyl and the corresponding higher chain and branched chain analogs thereof. The acyl radicals may also contain one or more  
5 double bonds and/or an additional acid functional group, e.g., glutaryl or succinyl. The heteroaryl groups referred to above encompass aromatic heterocyclic groups containing 3-6 carbon atoms and one or more heteroatoms such as oxygen, nitrogen or sulfur.

10

The lower alkyl sulfonyl groups of the compounds of this invention are those containing from 1 to 7 carbon atoms and are typified by methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, t-butylsulfonyl and the like.

15

The term "aryl" as used herein refers to phenyl and lower alkyl substituted phenyl groups containing 6-10 carbon atoms and substituted by one or more substituent groups selected from among chloro, bromo, fluoro, carboxy, lower  
20 alkyl, hydroxy, or lower monoalkylamino, lower dialkylamino, and lower alkoxy.

Accordingly, where identified herein, the term "inhibitors of advanced glycosylation" is intended to  
25 encompass both the compounds such as aminoguanidine, lysine and  $\alpha$ -hydrazinohistidine, and other agents as generically expressed hereinabove and as may be contained in other related patent applications and patents issued subsequently to U.S. Patent No. 4,983,604 and having  
30 reference thereto.

In the following examples, the effect of AGE-lipids on atherogenesis was demonstrated by the reaction of glucose with the amine-containing lipid, phosphatidylethanolamine  
35 (PE). In the presence of EDTA, a nitrogen atmosphere, and at physiological pH and temperature, glucose (5-500 mM) reacts with PE in a time- and concentration-dependent

manner to form lipid-soluble products with the spectroscopic properties of AGEs.

AGE formation induced fatty acid oxidation with reaction kinetics that paralleled AGE-associated absorbance and fluorescence. Incubation of glucose with phosphatidylcholine (PC), in which the amine is blocked and unable to react with glucose to initiate AGE formation, resulted in neither spectroscopic changes nor fatty acid oxidation.

Aminoguanidine prevented lipid-AGE formation and lipid oxidation of PE. Again without limiting the invention to a specific reaction mechanism, aminoguanidine may have inhibited fatty acid oxidation by two mechanisms: first, the formation of lipid-associated AGEs was inhibited. Second, the direct reaction with malonyl dialdehyde-like fatty acid oxidation products was inhibited. Lipids containing reactive groups, e.g., primary amino groups therefore react readily with reducing sugars to form AGEs and this induces fatty acid oxidation. Aminoguanidine inhibited the formation of lipid associated AGEs and reacts directly with malonyl-dialdehyde like fatty acid oxidation products.

Further details of the above and additional studies are presented below.

#### EXAMPLE 1

To ascertain whether and to what extent lipids are capable of reacting to form advanced glycosylation endproducts, the lipids phosphatidylethanolamine and phosphatidylcholine were placed into contact with a sugar, preferably a reducing sugar, and allowed to incubate together. Aliquots of the incubation mixture were thereafter assayed as described below, for evidence

of the presence of lipid-associated or lipid-attached  
AGES. The accumulation of AGES indicates spontaneous  
formation of AGE-lipids by non-enzymatically mediated  
chemical reactions between lipid and sugar precursor  
5 compounds.

#### Methods

Lipid in the form of phosphatidylethanolamine (PE; L- $\alpha$ -  
phosphatidylethanolamine, dioleoyl) (1,2-di[(cis)-9-  
10 octadecenoyl]-sn-glycero-3-phosphoethanolamine) or  
phosphatidylcholine (PC) (L- $\alpha$ -phosphatidylcholine,  
dioleoyl) 1,2-di[(cis)-9-octadecenoyl]-sn-glycero-3-  
phosphocholine was incubated with glucose (Glu) (L-D-  
glucose) as follows: Ten mg of PE or PC in  $\text{CHCl}_3$  solution  
15 was evaporated to dryness. To this sample was added 1 ml  
of glucose (0.5 M) in  $\text{NaPO}_4$  buffer (100 mM, pH 7.4)  
containing EDTA (1 mM). This solution was previously  
deaerated by freeze/thawing and saturating the solution  
with  $\text{N}_2$  gas. The dried lipid was dispersed in the glucose  
20 solution by immersing the sealed tube in a bath sonicator  
for 30 minutes. Tubes were then placed at  $37^\circ\text{C}$ , in the  
dark, and incubated for the indicated period of time. At  
intervals, separate tubes continuing parallel incubations  
(aliquots) were removed, and the lipids extracted for  
25 analysis as follows.

Aliquots were shaken with 1 ml of chloroform/methanol  
(2:1) for ten minutes. After removal of the organic  
layer, this extraction was repeated twice. The organic  
30 layer was then back extracted twice with ice cold,  
deaerated  $\text{H}_2\text{O}$ . After evaporation, lipids were redissolved  
in chloroform/methanol (1:1) and analyzed by absorption  
spectroscopy ( $\text{OD}_{200-800}$  or  $\text{OD}_{360}$ ); or fluorescence  
spectroscopy (excitation wavelength (Ex) 360 nm, emission  
35 wavelength (Em) 440 nm).

The results are shown in Figures 1 and 2. Figure 1 shows the time dependent increase in absorbency at 360 nm, which absorbency is characteristic of AGEs and AGE-containing compounds. As shown Figure 1, incubation of  
5 PE with glucose leads to a significant accumulation of material with AGE-typical absorbance, but incubation of the PC with glucose produces almost none. This result suggests that the free amino group represented in PE may be required for AGE formation while the blocked amino  
10 group of PC lacks the reactivity to make AGE formation possible.

Figure 1 indicates that formation of OD<sub>360</sub> material depends on glucose concentration; less AGE-specific absorbance is  
15 found after incubation of PE with 50 mM glucose than after parallel incubations with 500 mM glucose.

Figure 1 also indicates that aminoguanidine, an inhibitor of AGE formation on proteins, inhibits AGE-lipid  
20 formation as indicated by lower AGE-specific OD<sub>360</sub> values in incubations for PE with 0.5 M glucose and 0.1 M aminoguanidine than in parallel incubations of PE and glucose without aminoguanidine.

Figure 2 shows parallel measurements of fluorescence intensity on the same sets of samples. The results and conclusions are as above. AGE-lipids form spontaneously in incubations of PE and glucose, but not in incubations of PC and glucose. AGE-lipid formation is glucose  
25 concentration-dependent, and aminoguanidine inhibits AGE-lipid formation as monitored by the accumulation of AGE-typical fluorescence material.  
30

Figure 4 shows the changes in the ultraviolet and visible absorbance spectrum (200-500 nm) that occur over time  
35 when PE is incubated with 0.5M glucose as described above. These changes are characteristic of the formation

of AGEs and AGE-like chromophores. Figure 4 shows that more AGE-typical UV absorbance occurs with progressively longer incubations.

- 5 Figures 5 and 6 show the dependence of AGE-lipid formation on glucose concentration in the incubation mixture. Incubation of PE with glucose for 50 days leads to AGE-specific absorbance (Figure 5); and fluorescence (Figure 6). The glucose concentration dependence of  
10 lipid oxidation is shown in Figure 7.

### EXAMPLE 2

- To demonstrate that AGE-lipid formation is associated  
15 with changes in lipid oxidation, the accumulation of malonyldialdehyde (MDA)-like oxidation products was measured in samples from the incubations described above.

#### Methods

- 20 Lipid peroxidation products were quantified by the thiobarbituric acid reactive substances methods (TBARS; *PROC. NATL. ACAD. SCI. USA* 81:3883-3887). Briefly, 0.1 ml of lipid extract was added to 0.2 ml of TBA reagent (0.37% thiobarbituric acid, 10% trichloroacetic acid) and  
25 heated to 100°C for 30 minutes. n-Butanol extractable material (1 ml) was then analyzed by fluorescence spectroscopy (emission at 553 nm upon excitation at 515 nm). Thiobarbituric acid-reactive substances were quantitated by comparison of duplicate experimental  
30 samples to an MDA standard curve that was obtained by assaying in duplicate, 0.1-20 nmole of MDA. Oxidative modification values are expressed as MDA equivalents (pmMDA(eq)/μg lipid).

#### Results

Figures 3 and 7 show that lipid oxidation increased in conjunction with AGE-lipid formation. Specifically,

incubation of PE with glucose led to lipid oxidation in a time- (Figure 3) and glucose concentration- (Figure 7) dependent fashion. Incubations of PC with glucose led to little or no lipid oxidation (Figure 3), and  
5 aminoguanidine inhibited oxidation of lipid in PE/glucose incubations (Figure 3).

### EXAMPLE 3

10 The formation of AGEs on lipids was additionally assessed by AGE-specific ELISA.

#### Methods

Lipids (PE or PC) were incubated with glucose as  
15 described above. AGE content was quantitated by ELISA using a specific anti-AGE antibody (see Makita et al., *J. BIOL. CHEM.* (1992), 267:5133-5138). Protein-linked AGEs were measured by competitive ELISA utilizing an AGE standard synthesized by incubation of glucose with BSA.  
20 In this ELISA, 1.0 U of AGE activity is defined as the amount of antibody-reactive material that is equivalent to 1.0  $\mu$ g of AGE-BSA standard. Lipid-derived AGEs were measured in a direct, non-competitive ELISA as follows. For each sample, triplicate 100  $\mu$ l aliquots of lipid-  
25 soluble material (dissolved in methanol) were added to round-bottom, 96 well plates and the solvent evaporated. The wells then were washed three times with PBS/0.05% Tween-20. Antiserum (final dilution 1/1000) was added, the plates were incubated for 1 hour at room temperature,  
30 and the wells washed and processed as described for the competitive ELISA. Control samples were developed with pre-immune serum in place of anti-AGE antiserum. Results were quantitated with reference to a standard curve that was obtained by assaying dilutions of AGE-BSA standard  
35 that were absorbed to plates in a concentration range from 0.3 ng/ml to 3  $\mu$ g/ml.

Results

Table 1 shows the formation of AGE-lipids from phosphatidylethanolamine versus the control lipid phosphatidylcholine (in which the amino group is blocked and thus thought to be prevented from reacting with the reducing sugar glucose).

TABLE 1

10	<u>Incubation Time</u>	<u>AGE, Units/mg lipid</u>	
	Days	PE + glucose	PC + glucose
	0	<0.005	<0.005
	10	0.024±0.003	<0.005
15	20	0.20± 0.03	<0.005
	30	0.13± 0.02	<0.005
	40	0.15± 0.02	<0.005
	50	0.13± 0.02	<0.005
20			

EXAMPLE 425 Reaction between aminoguanidine and malonyldialdehyde

Example 2 showed that AGE-lipid formation is accompanied by a parallel increase in lipid oxidation as measured by an increase in the concentration of MDA-like substances.

30 It is notable that this oxidation of lipids occurred without added metals, such as copper, which are commonly employed to initiate lipid oxidation. Additionally, the above examples indicate that aminoguanidine prevents both AGE-lipid formation and lipid oxidation.

35

To demonstrate that aminoguanidine can react directly with MDA-like aldehydes to prevent their reaction with proteins, aminoguanidine was incubated with MDA.

40 Methods

Malonyldialdehyde (MDA) standard solutions (0.5 ml) were prepared by dilution of malonaldehyde bis(diethyl acetal)

into H<sub>2</sub>O. Aminoguanidine HCl (0.5 ml) was added, followed by 0.2 ml of the TBA reagent described above. The solution was incubated at room temperature for 10 minutes and TBARS measured by specific fluorescence as described  
5 hereinabove.

### Results

The results are shown in Figures 8A and B. Figure 8A shows the progressive inhibition of thiobarbiturate reactivity of MDA (indicated by relative fluorescence) by  
10 increasing amounts of aminoguanidine. Thus, aminoguanidine may inhibit protein modification by lipid oxidation products by quenching reactive aldehydes before the latter can participate extensively in subsequent  
15 modification of protein amino groups.

Figure 8B plots one of the latter data sets from Figure 8A, illustrating the increase in inhibition (A) of the fixed initial amount (10 mM MDA) of thiobarbiturate  
20 activity by increasing concentrations of added aminoguanidine.

### EXAMPLE 5

25 To define further the relationship between advanced glycosylation and LDL oxidation *in vivo*, LDL was isolated from plasma obtained from either non-diabetic or diabetic individuals and analyzed for the presence of lipid-AGEs, apoprotein-AGEs, and oxidative modification. These  
30 specimens were obtained from 8 normoglycemic, non-diabetic controls and 16 patients with Type I or Type II diabetes mellitus.

### Methods

35 Plasma LDL ( $d = 1.025-1.063$  g/ml) was isolated from healthy, non-hyperglycemic individuals and patients with diabetes mellitus by sequential ultracentrifugation,

using 2.7 mM EDTA. The isolated and re-centrifuged LDL was dialyzed extensively against PBS containing 2.7 mM EDTA and 0.2 mM BHT. LDL was sterile filtered before further use and the protein content determined by the Lowry method. The non-diabetic patient group (n = 8) had a mean age of  $34.6 \pm 9.6$  years. The diabetic group (n = 16) consisted of 5 patients with Type I diabetes and 11 patients with Type II diabetes. The mean age was  $55.5 \pm 16.3$  years and the mean duration of diabetes was  $11.9 \pm 5.6$  years. The mean hemoglobin A<sub>1c</sub> level was  $10.0\% \pm 1.7\%$ . The P values were calculated by the unpaired Student's t-test statistic for comparison between groups.

### Results

The LDL was analyzed for oxidative modification and then fractionated into lipid and apoprotein components for AGE-ELISA measurements (Figure 9). In agreement with prior studies, LDL from diabetic individuals was observed to have undergone significantly greater oxidative modification than the LDL from non-diabetic individuals [Normal, Non-diabetics (NL): (n=8)  $3.7 \pm 1.25$  pm MDA equivalents/ $\mu$ g LDL; Diabetics (DM): (n=16)  $6.8 \pm 1.2$  pm MDA equivalents/ $\mu$ g LDL (Mean  $\pm$  SD),  $P < 0.0001$ ]. Of significance, both the lipid- and the apoprotein-linked AGEs in the diabetic LDL specimens were found to be markedly elevated when compared to the LDL specimens obtained from non-diabetic individuals. Lipid-AGE levels were elevated almost 4-fold in diabetic patients [Normal, non-diabetic (NL): (n=8)  $0.11 \pm 0.03$  Units of AGE/ $\mu$ g lipid; Diabetics (DM): (n=16)  $0.41 \pm 0.25$  Units of AGE/ $\mu$ g lipid,  $P < 0.005$ ]. Apoprotein-AGE levels were increased approximately 2-fold in the diabetic samples [NL: (n=8)  $0.0028 \pm 0.0006$  Units of AGE/ $\mu$ g apoprotein; DM: (n=16)  $0.0068 \pm 0.004$  Units of AGE/ $\mu$ g apoprotein,  $P < 0.0001$ ].

35

These measurements revealed a similar quantitative ratio between LDL oxidation and the level of AGE-lipid and AGE-

apoprotein that was similar to that observed during LDL incubation *in vitro* (Figure 10). There also appeared to be a marked increase in the level of lipid-AGEs relative to the level of apoprotein-associated AGEs. Linear regression analysis of these data revealed significant correlation between the level AGE modification and LDL oxidation. For the measurement of AGE-apoprotein versus LDL oxidation, this analysis showed a correlation coefficient of  $r=0.52$  and  $P<0.01$ . For AGE-lipid versus LDL oxidation, the corresponding values were  $r=0.63$  and  $P<0.005$ .

#### EXAMPLE 6

It was also postulated that contiguous basic residues (Arg-Lys-Arg) within the receptor-binding domain of apo B might serve as a reactive site for AGE formation, thus preventing normal pathways of LDL clearance. To begin to address this hypothesis, LDL levels were examined in 10 diabetic patients enrolled in a 28-day trial of aminoguanidine (AG), a pharmacological inhibitor of advanced glycosylation.

LDL levels in 10 diabetic patients enrolled in a 28-day trial of aminoguanidine (AG) were measured by the AGE-specific ELISA of Example 3. The efficacy of AG therapy was assessed by reduction in the level of hemoglobin-AGE (Hb-AGE), a circulating marker of advanced glycosylation. The results are given in Figure 14 and Table 2, below. Table 2 also includes additional data relating to Hb-AGE.

TABLE 2

<u>Patient</u>		
<u>Group</u>	<u>Hb-AGE</u>	<u>LDL</u>
Placebo	8.9 $\pm$ 0.6% reduction	2.0 $\pm$ 0.2% reduction

AG  
treatment     $27.5 \pm 1.6\%$  reduction     $29.8 \pm 3.1\%$  reduction  
                    Mean  $\pm$  SD,  $p < 0.0025$     Mean  $\pm$  SD,  $p < 0.002$

- 5    Inhibition of AGE formation was associated with a 30% decrease in LDL levels, as illustrated in Figure 14.

This study suggests that the advanced glycosylation may account for elevated LDL levels, and that aminoguanidine  
10    therapy may serve to improve LDL clearance and diminish the risk of atherogenesis in diabetic patients.

#### EXAMPLE 7

- 15    To determine whether human AGE-peptides can react with plasma lipoproteins, AGE-peptides isolated from diabetic sera were incubated with human LDL, in the presence or absence of the AGE-inhibitor aminoguanidine (300 mM) for 14 days and the results compared to controls (LDL only)  
20    and a parallel incubation of LDL with glucose. AGE levels in apo B and in lipid fractions of LDL were measured by the AGE-specific ELISA procedure of Example 3, and the results given below in Table 3, and in Figures 11A and 11B. In addition, LDL oxidation was measured as  
25    in Example 4, and the AGE-formation was found to parallel LDL-oxidation.

As shown in Table 3 below, marked increases in AGE content of apo B, and of lipid fraction of LDL were noted  
30    as a function of time compared to control samples. These values far exceeded those obtained using glucose. AGE-formation paralleled LDL oxidation. In the presence of the AGE-inhibitor aminoguanidine, AGE-formation, as well as lipid oxidation, was markedly inhibited.

- 35    In conclusion, circulating AGE-peptides are an important *in vivo* source of AGE-lipids, and oxidative modification

of plasma LDL, in excess of and independent of glucose. Aminoguanidine may be of therapeutic benefit in diabetics, where elevated AGE-peptide levels and hyperlipidemia may be causally linked to accelerated  
5 atherosclerosis.

TABLE 3

Sample	AGE Level		Oxidized LDL Level
Control (LDL only)	Apo B	2.0 AGE U/mg	3 nmoles MDA/mg
	lipid	130 AGE U/mg	
Glucose (100 mM) + LDL	Apo B	7 AGE U/mg	
	lipid	630 AGE U/mg	
LDL + AGE-peptides	Apo B	47 AGE U/mg	56 nmoles MDA/mg
	lipid	2200 AGE U/mg	
LDL + AGE-peptides + AG	Apo B	7 AGE U/mg	12 nmoles MDA/mg
	lipid	290 AGE U/mg	

EXAMPLE 8

The AGE-specific ELISA of Example 3 was used to measure AGE moieties attached to the apo B and lipid components of LDL isolated from normal controls (n=17) and diabetic patients (n=43). The results are shown below in Table 4. Additional data reflecting the study of lipid oxidation in these patient samples are presented in Figures 12A-12C.

TABLE 4

<u>Patient Type</u>	<u>AGE level (lipid)</u>	<u>AGE level ApoB</u>
5 Control	109 AGE U/mg	2.9 AGE U/mg
Diabetic patients with none or single complication	317 AGE U/mg p < 0.005	4.6 AGE U/mg p < 0.001
10 Diabetic patients with multiple complications	552 AGE U/mg p < 0.001	8.4 AGE U/mg p < 0.001
15 Diabetic patients with severe diabetic nephropathy (ESRD)	3270 AGE U/mg p < 0.001	71 AGE U/mg p < 0.001

These data indicate that circulating AGE-LDL levels correlate closely with the number and severity of diabetic complications and support an etiopathological relationship between AGE-modification and both the micro- and macro-vascular complications of diabetes since LDL from diabetic patients with multiple complications contained five-fold higher levels of AGE-lipid and almost three-fold higher levels of AGE-apo B when compared to normal controls. Diabetics with severe diabetic nephropathy (ESRD) showed marked elevation of AGE-modified LDL when compared to diabetic patients without renal involvement.

The results also indicate the AGE-lipid modification was associated with proportionally increased lipid oxidation within each group of patients (non-diabetic: 3.7 nmoles/mg; (0-1 complications): 5.2 nmoles/mg (>4 complications): 8.4 nmoles/mg [measured as nmole MDA equiv/mg LDL]).

20

#### EXAMPLE 9

An additional patient population was examined to provide data cumulative with the data collected and evaluated in Example 8, above. Accordingly, to determine levels of circulating AGE-low density lipoprotein, apoprotein B, plasma LDL was collected from the selected patients as described in Example 8. Briefly, LDL was delipidated with methanol-ether 1:3 (V/V). Apo B was digested by incubating at 37°C for 24 hours by using Proteinase K, (1 mg/ml). These samples were inactivated by heating at 70°C for 1 hour. AGE levels were determined by ELISA as described in Example 3. The results are presented in Figure 13.

35

To obtain a measure of the *in vivo* "reactivity" of AGE-peptides, AGE levels were determined on a short-lived

plasma protein, apoprotein B, in patients with and without diabetes. As shown in Figure 13, marked elevations of AGE-Apo B were found in LDL from diabetic (mean  $69.4 \pm 21.7$  AGE U/mg,  $p < 0.0001$ ), as well as non-diabetic patients with ESRD (mean  $27.6 \pm 16.5$  AGE U/mg,  $p < 0.0001$ ) compared to normals ( $2.8 \pm 0.5$  AGE U/mg), and diabetics with normal renal function (mean  $3.9 \pm 1.0$  AGE U/mg). Since non-diabetics with ESRD are normoglycemic, with normal levels of HbA<sub>1c</sub>, the data clearly suggest that glucose is not the only source of AGE modification. This is confirmatory of the observation noted in Example 8, above.

#### DISCUSSION

The data presented here provide an important link between elevated levels of plasma AGEs and accelerated vasculopathy associated with ESRD, consisting of the striking ability of endogenous AGE-peptides to "react" with key proteins, such as collagen and lipoproteins. LDL apoprotein B is a short-lived plasma protein, long implicated in atherogenesis. The efficient generation of AGE-apo B by AGE-peptides *in vivo* suggested a possible, *in vivo* marker for the "toxicity" of AGE-peptides. The patient data on circulating AGE-apo B supported this notion.

The level of AGE modification of plasma LDL/Apo B in patients with ESRD was significantly elevated compared to the level of the normal subjects (ten-fold for non-diabetic (ESRD) and twenty-five fold for diabetic (ESRD) patients). Given the relatively short half-life of the LDL particle in blood, the degree of AGE modification in ESRD patients cannot be attributed solely to ambient glucose or other "intermediate" glycosylation products found in plasma. The contribution of these agents in the non-diabetic ESRD patients is also improbable given the normal glucose and HbA<sub>1c</sub> levels in these non-diabetic

patients. Instead, a principal role can be attributed to the so-called "AGE-peptides", or low molecular weight blood-borne AGE-modified species. This is supported by the relatively elevated levels of AGE-peptide in ESRD patients, whether diabetic or not. Further support is for this notion is provided by the relatively modest elevations of AGE-Apo B in diabetic patients with normal renal function, despite their hyperglycemia as reflected in elevated HbA<sub>1c</sub>.

10

This interpretation is consistent with the argument that the absence of renal function plays a more important role in total serum AGE accumulation than an increased rate of AGE formation due to hyperglycemia. It is further supported by the findings indicating the clearance of serum AGEs by the kidneys, as measured by urinary excretion, does not differ significantly between normal and diabetics, as long as renal function is preserved.

20 The following publications relate generally to advanced glycosylation endproducts and the reactions in which such products are involved.

"Function of Macrophage Receptor for Nonenzymatically Glycosylated Proteins is Modulated by Insulin Levels," Vlassara, Brownlee and Cerami, *DIABETES* (1986), Vol. 35 Supp. 1, Page 13a;

30 "Accumulation of Diabetic Rat Peripheral Nerve Myelin by Macrophages Increases with the Presence of Advanced Glycosylation Endproducts," Vlassara, H., Brownlee, M., and Cerami, A. J. *EXP. MED.* (1984), 160:197-207;

"Recognition and Uptake of Human Diabetic Peripheral Nerve Myelin by Macrophages," Vlassara, H., Brownlee, M., and Cerami, A. *DIABETES* (1985), 34(6):553-557;

"High-Affinity-Receptor-Mediated Uptake and Degradation of Glucose-Modified Proteins: A Potential Mechanism for the Removal of Senescent Macromolecules," Vlassara H., Brownlee, M., and Cerami, A., *PROC. NATL. ACAD. SCI. USA*  
5 (Sept. 1985), 82:5588-5592;

"Novel Macrophage Receptor for Glucose-Modified Proteins is Distinct from Previously Described Scavenger Receptors," Vlassara, H., Brownlee, M., and Cerami, A.  
10 *J. EXP. MED.* (1986), 164:1301-1309;

"Role of Nonenzymatic Glycosylation in Atherogenesis," Cerami, A., Vlassara, H., and Brownlee, M., *J. CELL. BIOCHEMISTRY* (1986), 30:111-120;  
15

"Characterization of a Solubilized Cell Surface Binding Protein on Macrophages Specific for Proteins Modified Nonenzymatically by Advanced Glycosylation Endproducts," Radoff, S., Vlassara, H. and Cerami, A., *ARCH. BIOCHEM. BIOPHYS.* (1988), 263(2): 418-423;  
20

"Isolation of a Surface Binding Protein Specific for Advanced Glycosylation Endproducts from the Murine Macrophage-Derived Cell Line Raw 264.7", Radoff, S.,  
25 Vlassara, H., and Cerami, A., *DIABETES*, (1990), 39:1510-1518;

"Two Novel Rat Liver Membrane Proteins that Bind Advanced Glycosylation Endproducts: Relationship to Macrophage  
30 Receptor for Glucose-Modified Proteins," Yang, Z., Makita, Z., Horii, Y., Brunelle, S., Cerami, A., Sehajpal, P., Suthanthiran, M. and Vlassara, H., *J. EXP. MED.*, (1991), 174:515-524.

35 The following listing of publications supplements those set forth above and corresponds by the numbers indicated to like references in the foregoing specification.

1. Witztum, J. L., and D. Steinberg. 1991. Role of oxidized low density lipoprotein in atherogenesis. *J. Clin. Invest.* 88:1785-1792.
- 5 2. Goldstein, J. L., Y. K. Ho, S. K. Basu, and M. S. Brown. 1979. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. *Proc. Natl. Acad. Sci. USA* 76:333-337.
- 10 3. Fogelman, A. M., J. S. Schechter, M. Hokom, J. S. Child, and P. A. Edwards. 1980. Malondialdehyde alteration of low density lipoprotein leads to cholesterol accumulation in human monocyte-macrophages. *Proc. Natl. Acad. Sci. USA* 77:2214-2218.
- 15 4. Sparrow, C. P., S. Parthasarathy, and D. Steinberg. 1989. A macrophage receptor that recognizes oxidized LDL but not acetylated LDL. *J. Biol. Chem.* 264:2599-2604.
- 20 5. Ross, R. 1986. The pathogenesis of atherosclerosis. An update. *New Eng. J. Med.* 314:488-500.
- 25 6. Quinn, M. T., S. Parthasarathy, L. G. Fong, and D. Steinberg. 1987. Oxidatively modified low density lipoprotein: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. *Proc. Natl. Acad. Sci. USA* 84: 2995-2998.
- 30 7. Hessler, J. R., D. W. Morel, L. J. Lewis, and G. M. Chisolm. 1983. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. *Arteriosclerosis* 3: 215-222.
- 35 8. Kugiyama, K., S. A. Kerns, J. D. Morrisett, R. Roberts, and P. D. Henry. 1990. Impairment of endothelium-dependent arterial relaxation by lysolecithin

in modified low-density lipoproteins. *Nature* 344: 160-162.

9. Rajavashisth, T. B., A. Andalibi, M. C. Territo, J. A. Berliner, M. Navab, A. M. Fogelman, and A. J. Lusis. 1990. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. *Nature* 344: 254-257.
10. Cushing, S. D., J. A. Berliner, A. J. Valente, M. Navab, F. Parhami, R. Gerrity, C. J. Schwartz, and A. M. Fogelman. 1990. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. *Proc. Natl. Acad. Sci. USA*. 87: 5134-5138.
11. Kita, T., Y. Nagano, M. Yokode, K. Ishii, N. Kume, A. Ooshima, H. Yoshida, and C. Kawai. 1987. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. *Proc. Natl. Acad. Sci. USA* 84:5928-5931.
12. Esterbauer, H. G. Jürgens, O. Quehenberger, and Koller, E. 1987. Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. *J. Lipid Res.* 28: 505-509.
13. Quehenberger, O., E. Koller, G. Jürgens, and H. Esterbauer. 1987. Investigation of lipid peroxidation in human low density lipoprotein. *Free Radical Res. Commun.* 3: 233-242.
14. Steinbrecher, U. P. 1987. Oxidation of human low density lipoprotein results in derivitization of lysine

residues of apolipoprotein B by lipid peroxide decomposition products. *J. Biol. Chem.* 262:3603-3608.

15. Steinbrecher, U. P., S. Parthasarathy, D. S. Leake,  
5 J. L. Witztum, and D. Steinberg. 1984. Modification of  
low density lipoprotein by endothelial cells involves  
lipid peroxidation and degradation of low density  
lipoprotein phospholipids. *Proc. Natl. Acad. Sci. USA* 81:  
3883-3887.
- 10 16. Parthasarathy, S., E. Wieland, and D. Steinberg.  
1989. A role for endothelial cell lipoxygenase in the  
oxidative modification of low density lipoprotein. *Proc.*  
*Natl. Acad. Sci. USA* 86:1046-1050.
- 15 17. Klaassen, C. D. 1985. Heavy metals and heavy metal  
antagonists, In Goodman and Gilman's The Pharmacological  
Basis of Therapeutics. A. G. Gilman, L. S. Goodman. T. W.  
Rall, and F. Murad. Macmillan, New York. 1605-1627.
- 20 18. Frei, B., Y. Yamamoto, D. Niclas, and B. N. Ames.  
1988. Evaluation of an isoluminol chemiluminescence assay  
for the detection of hydroperoxides in human blood  
plasma. *Anal. Biochem.* 175:120-130.
- 25 19. Frei, B., R. Stocker, and B. N. Ames. 1988.  
Antioxidant defenses and lipid peroxidation in human  
blood plasma. *Proc. Natl. Acad. Sci. USA* 85:9748-9752.
- 30 20. Bucala, R., and A. Cerami. 1992. Advanced  
glycosylation: chemistry, biology, and implications for  
diabetes and aging. *Adv. Pharmacol.* 23:1-34.
- 35 21. Njoroge, F. G., and V. M. Monnier. 1989. The  
chemistry of the Maillard reaction under physiological  
conditions: A review. *Prog. Clin. Biol. Res.* 304:85-107.

22. Brownlee, M., A. Cerami, and H. Vlassara. 1988. Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications. *N. Eng. J. Med.* 318:1315-1321.
- 5 23. Monnier, V. M., R. R. Kohn, and A. Cerami. 1984. Accelerated age-related browning of human collagen in diabetes mellitus. *Proc. Natl. Acad. Sci. USA.* 81:583-587.
- 10 24. Bucala, R., K. J. Tracey, and A. Cerami. 1991. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. *J. Clin. Invest.* 87:432-438.
- 15 25. Vlassara, H., M. Brownlee, and A. Cerami. 1985. High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: A potential mechanism for the removal of senescent macromolecules. *Proc. Natl. Acad. Sci USA* 82:5588-5592.
- 20 26. Esposito, C., H. Gerlach, J. Brett, D. Stern, and H. Vlassara. 1989. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. *J. Exp. Med.* 170:1387-1407.
- 25 27. Vlassara, H., M. Brownlee, K. R. Manogue, C. A. Dinarello, and A. Pasagian. 1988. Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodelling. *Science* 240:1546-1548.
- 30 28. Jain, S. K., R. McVie, J. Duett, and J. J. Herbst. 1989. Erythrocyte membrane lipid peroxidation and glycosylated hemoglobin in diabetes. *Diabetes* 38:1539-1543.
- 35

29. Nishigaki, I., M. Hagihara, H. Tsunekawa, M. Maseki, and K. Yagi. 1981. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. *Biochem. Med.* 25:373-378.
- 5
30. Armstrong, D. N. Abdella, A. Salman, N. Miller, E. A. Rahman, and M. Bojanczyk. 1992. Relationship of lipid peroxides to diabetic complications. *J. Diabetes Complications* 6:116-122.
- 10
31. London, E., and G. W. Feigenson. 1978. A convenient and sensitive fluorescence assay for phospholipid vesicles using diphenylhexatriene. *Anal. Biochem.* 88:203-211.
- 15
32. Jain, S. K., and D. Subrahmanyam. 1978. Two dimensional thin-layer chromatography of polar lipids. *Ital. J. Biochem.* 27:11-18.
- 20
33. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. Distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. *J. Clin. Invest.* 34:1345-1353.
- 25
34. Lowry, O., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with Folin phenol reagent. *J. Biol. Chem.* 193: 265-275.
- 30
35. Makita, Z., H. Vlassara, A. Cerami, and R. Bucala. 1992. Immunochemical detection of advanced glycosylation end products *in vivo*. *J. Biol. Chem.* 267: 5133-5138.
- 35
36. Makita, Z., H. Vlassara, E. Rayfield, K. Cartwright, E. Friedman, R. Rodby, A. Cerami, and R. Bucala. 1992. Hemoglobin-AGE: A circulating marker of advanced glycosylation. *Science* 258:651-653.

37. Kikugawa, K., T. Kojima, S. Yamaki, and H. Kosugi. 1992. Interpretation of the thiobarbituric acid reactivity of rat liver and brain homogenates in the presence of ferric ion and ethylenediaminetetraacetic acid. *Anal. Biochem.* 202:249-255.
38. Ohkawa, H., N. Ohishi, and K. Yagi. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal. Biochem.* 95:351-358.
39. Chen, H.-J. C., and A. Cerami. 1992. Mechanism of inhibition of advanced glycosylation by aminoguanidine in vitro. *J. Carbohydrate Chem.* (in press).
40. Picard, S., S. Parthasarathy, J. Fruebis, and J. L. Witztum. 1992. Aminoguanidine inhibits oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptors. *Proc. Natl. Acad. Sci. USA* 89:6876-6880.
41. Hicks, M., L. Delbridge, D. K. Yue, and T. S. Reeve. 1988. Catalysis of lipid peroxidation by glucose and glycosylated collagen. *Biochem. Biophys. Res. Commun.* 151:649-655.
42. Mullarkey, C. J., D. Edelstein, and M. Brownlee. 1990. Free radical generation by early glycation products: A mechanism for accelerated atherogenesis in diabetes. *Biochem. Biophys. Res. Commun.* 173:932-939.
43. Pongor, S., P.C. Ulrich, F. A. Bencsath, and A. Cerami. 1984. Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. *Proc. Natl. Acad. Sci. USA*, 81:2684-2688.

44. Ahmed, M. U., J. A. Dunn, M. D. Walla, S. R. Thorpe, and J. W. Baynes. 1988. Oxidative degradation of glucose adducts to protein. *J. Biol. Chem.* 263:8816-8821.
- 5 45. Grandhee, S.K., and V. M. Monnier. 1991. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. *J. Biol. Chem.* 266:11649-11653.
- 10 46. Namiki, M., and T. Hayashi. 1981. Formation of novel free radical products in an early stage of Maillard reaction. *Prog. Fd. Nutr. Sci.* 5:81-91.
47. Tsuchida, M., T. Miura, and K. Aibara. 1987.
- 15 48. Lipofuscin and lipofuscin-like substances. *Chem. Phys. Lipids.* 44:297-325.
49. T. Soulis-Liparota, M. Cooper, D. Papazoglou, B. Clarke, and G. Jerums. 1991. Retardation by
- 20 aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. *Diabetes* 40:1328-1334.
49. Hammes, H. P., S. Martin, K. Federlin, K. Geisen, and M. Brownlee. 1991. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. *Proc. Natl. Acad. Sci. USA* 88:11555-11558.
- 25 49. Hammes, H. P., S. Martin, K. Federlin, K. Geisen, and M. Brownlee. 1991. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. *Proc. Natl. Acad. Sci. USA* 88:11555-11558.
- 30 50. Yagihashi, S., M. Kamijo, M. Baba, N. Yagihashi, and K. Nagai, 1992. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. *Diabetes* 41:47-52.
- 35 51. O'Brien, R. C., S. Panagiotopoulos, M. E. Cooper, and G. Jerums. 1992. Anti-atherogenic effect of

aminoguanidine, an inhibitor of advanced glycation.  
*Diabetes* 41, (Suppl. 1) 16A.

This invention may be embodied in other forms or carried  
5 out in other ways without departing from the spirit or  
essential characteristics thereof. The present  
disclosure is therefore to be considered as in all  
respects illustrative and not restrictive, the scope of  
the invention being indicated by the appended Claims, and  
10 all changes which come within the meaning and range of  
equivalency are intended to be embraced therein.

WHAT IS CLAIMED IS:

- 1 1. A method of modulating lipid oxidation in a mammal  
2 comprising administering to said mammal a lipid  
3 oxidation-modulating effective amount of an agent capable  
4 of controlling the formation of AGEs in said mammal.
- 1 2. The method of Claim 1 comprising a method for  
2 inhibiting said lipid oxidation, wherein said agent is  
3 capable of inhibiting the formation of said AGEs.
- 1 3. The method of either of Claims 1 or 2, wherein said  
2 AGEs comprise AGE-lipids.
- 1 4. The method of Claim 3 wherein said AGE-lipids are  
2 formed from lipid-related materials, and said lipid-  
3 related materials are selected from amine-containing  
4 lipids, low-density lipoproteins, and apolipoproteins.
- 1 5. The method of Claim 4, wherein said apolipoproteins  
2 comprise apolipoprotein B (apo B).
- 1 6. The method of Claim 2, comprising a method for  
2 lowering low-density lipoprotein levels in said mammal.
- 1 7. The method of Claim 2, comprising a method for the  
2 prevention and/or treatment of end stage renal disease.
- 1 8. The method of Claim 2, comprising a method for the  
2 prevention and/or treatment of atherosclerosis.
- 1 9. The method of Claim 2, comprising a method for the  
2 prevention and/or treatment of hypercholesterolemia.
- 1 10. A method of modulating lipid metabolism in a mammal  
2 in need of such treatment comprising administering to  
3 said mammal a lipid metabolism-modulating effective

4 amount of an agent capable of modifying the recognition  
 5 and removal of lipids and lipid-related materials from  
 6 serum, wherein said agent is capable of controlling the  
 7 formation, accumulation and/or activity of AGEs.

1 11. The method of Claim 10, wherein said agent is  
 2 selected from the group consisting of antibodies against  
 3 advanced glycosylation endproducts, ligands capable of  
 4 binding and/or neutralizing advanced glycosylation  
 5 endproducts, receptors for advanced glycosylation  
 6 endproducts, and compounds capable of inhibiting the  
 7 formation of advanced glycosylation endproducts.


1 12. The method of Claim 11, wherein said compounds  
 2 capable of inhibiting the formation of advanced  
 3 glycosylation endproducts are capable of reacting with an  
 4 active carbonyl moiety on an early glycosylation product.

1 13. The method of Claim 12, wherein said compound is  
 2 selected from the group consisting of aminoguanidine,  $\alpha$ -  
 3 hydrazinohistidine, lysine, an analog of aminoguanidine,  
 4 and mixtures thereof.

1 14. The method of Claim 13, wherein said analog is  
 2 selected from the group consisting of hydrazine  
 3 derivatives of the formula:



7 wherein R is a group of the formula



15 , and

16  $R_1$  is hydrogen or a lower alkyl group of 1-6 carbon  
 17 atoms, a hydroxyethyl group, or together with  $R_2$  or  $R_4$  may  
 18 be a lower alkylene bridge of 2-4 carbon atoms;

19  $R_2$  is hydrogen, amino, hydroxy, a lower alkyl group  
 20 of 1-6 carbon atoms, or together with  $R_1$  or  $R_3$  is a lower  
 21 alkylene bridge of 2-4 carbon atoms;  $R_2$  may also be an  
 22 aminoalkylene group of the formula



26 wherein  $n$  is an integer of 2-7 and  $R_6$  and  $R_7$  are  
 27 independently a lower alkyl group of 1-6 carbon atoms or  
 28 together form a part of a cycloalkyl or heterocyclic ring  
 29 containing from 1 to 2 heteroatoms, of which at least one  
 30 is nitrogen; and the second of said heteroatoms is  
 31 selected from the group consisting of nitrogen, oxygen,  
 32 and sulfur; with the proviso that when the second of said  
 33 heteroatoms of the heterocyclic ring is nitrogen and  
 34 forms a piperazine ring; it may be optionally substituted  
 35 by a substituent that is identical to the portion of the  
 36 compound on the first nitrogen of the piperazine ring;

37  $R_3$  is hydrogen, a lower alkyl group of 1-6 carbon  
 38 atoms, or together with  $R_2$  or  $R_4$  is a lower alkylene  
 39 bridge of 2-4 carbon atoms;

40  $R_4$  is hydrogen, a lower alkyl group of 1-6 carbon  
 41 atoms or together with  $R_1$  or  $R_3$  is a lower alkylene bridge  
 42 of 2-4 carbon atoms; or an amino group;

43  $R_5$  is hydrogen, or a lower alkyl group of 1-6 carbon  
 44 atoms; with the proviso that at least one of  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$   
 45 or  $R_5$  is other than hydrogen; or  $R$  is an acyl or a lower  
 46 alkylsulfonyl group of up to 10 carbon atoms and  $R_1$  is  
 47 hydrogen; and their pharmaceutically acceptable acid  
 48 addition salts.

1 15. A method of modulating lipid metabolism in a mammal  
 2 in need of such treatment comprising administering to

3 said mammal a lipid metabolism-modulating effective  
4 amount of an agent capable of modifying the recognition  
5 and removal of lipids and lipid-related materials from  
6 serum, wherein said agent is capable of inhibiting the  
7 blockade of the LDL receptor binding domain of apo B by  
8 an advanced glycosylation endproduct.

1 16. The method of Claim 15, wherein said agent is  
2 capable of preferentially binding to advanced  
3 glycosylation endproducts.

1 17. The method of Claim 16, wherein said agent is  
2 selected from the group consisting of an antibody to  
3 advanced glycosylation endproducts, and a receptor for  
4 advanced glycosylation endproducts.

1 18. The method of Claim 15, wherein said LDL receptor  
2 binding domain of apo B contains at least one active site  
3 amenable to the formation of an advanced glycosylation  
4 endproduct, and said agent is capable of inhibiting said  
5 advanced glycosylation endproduct from forming at said  
6 site.

1 19. The method of Claim 18, wherein said agent is  
2 capable of inhibiting the formation of said advanced  
3 glycosylation endproduct at said site by preferentially  
4 binding to said site.

1 20. A method for estimating the course and extent of *in*  
2 *vivo* lipid oxidation in a mammal comprising measuring the  
3 presence and amount of AGE-lipids in said mammal.

1 21. The method of Claim 20, wherein said AGE-lipids are  
2 measured by an *in vitro* procedure.

1 22. The method of Claim 20, comprising the steps of:

- 2           A.    preparing at least one biological sample  
3 taken from said mammal in which said AGE-lipids are  
4 suspected to be present;
- 5           B.    immobilizing a material selected from the  
6 group consisting of the biological sample of Step A. and  
7 a binding partner to AGE-lipid or AGE-bearing lipid-  
8 related material, on a suitable substrate, and labeling  
9 one of the materials not immobilized;
- 10          C.    incubating said sample with said binding  
11 partner for a period of time sufficient for said binding  
12 partner to become bound to any AGE-lipid or AGE-bearing  
13 lipid-related material present in said sample;
- 14          D.    removing any unbound material from Step  
15 C.; and
- 16          E.    comparing the amount of label bound to  
17 said sample to a standard.
- 1   23.   The method of Claim 22, wherein said binding partner  
2 is selected from the group consisting of a receptor for  
3 an AGE, and an antibody reactive with or capable of  
4 binding to said AGE-lipid.
- 1   24.   The method of Claim 23, wherein said antibody to  
2 said AGE-lipid is selected from the group consisting of  
3 polyclonal antibodies, monoclonal antibodies, and  
4 chimeric antibodies.
- 1   25.   The method of Claim 20 comprising a method for  
2 monitoring the level of low density lipoprotein in said  
3 mammal.
- 1   26.   The method of Claim 20, comprising a method for  
2 diagnosing the likelihood or onset, and/or for monitoring  
3 the course and severity of a pathology selected from  
4 atherosclerosis, vascular disease, diabetes, diabetic  
5 nephropathy, and hypercholesterolemia.

1 27. A method of testing the ability of a drug or other  
2 entity to prevent blockade of the LDL receptor binding  
3 domain on apo B, which comprises disposing a quantity of  
4 apo B with unbound LDL receptor binding domain in a  
5 suitable medium, simultaneously adding a quantity of an  
6 material capable of forming an AGE on said binding  
7 domain, and the drug under test, and thereafter measuring  
8 the quantity of AGE-apo B, if any, that is formed.

1 28. An AGE-lipid comprised of the reaction product of a  
2 lipid containing an AGE-reactive group reacted with an  
3 advanced glycosylation endproduct or a compound which  
4 forms advanced glycosylation endproducts.

1 29. An AGE-lipid according to Claim 28 wherein the AGE-  
2 reactive group of the lipid is a primary amino group.

1 30. An AGE-lipid according to Claim 29 wherein the lipid  
2 portion is selected from the group consisting of amine-  
3 containing lipids, lipoproteins, and apolipoproteins.

1 31. An AGE-lipid according to Claim 28 wherein the  
2 advanced glycosylation endproduct or a compound which  
3 forms advanced glycosylation endproducts is or derives  
4 from a reducing sugar.

1 32. An AGE-lipid according to Claim 31 wherein the  
2 compound which forms advanced glycosylation endproducts  
3 is selected from the group consisting of glucose,  
4 fructose, ribose and glucose-6-phosphate.

1 33. A method of preparing an AGE-lipid comprising  
2 incubating a lipid or lipid-related material containing  
3 an AGE-reactive group with an advanced glycosylation  
4 endproduct or a compound which forms advanced  
5 glycosylation endproducts.

- 1 34. The method of Claim 33 wherein the lipid or lipid-  
2 related material is selected from the group consisting of  
3 amine-containing lipids, lipoproteins, and  
4 apolipoproteins.
- 1 35. A pharmaceutical composition comprised of an AGE-  
2 lipid according to Claim 28 in combination with a  
3 pharmaceutically acceptable carrier.
- 1 36. A pharmaceutical composition according to Claim 35  
2 wherein the AGE-lipid is selected from the group  
3 consisting of AGE-phospholipids, AGE-low density  
4 lipoproteins, and AGE-apolipoproteins.
- 1 37. A pharmaceutical composition according to Claim 35  
2 wherein the AGE-lipid or pharmaceutically acceptable  
3 carrier is effective for transdermally delivering a  
4 therapeutically active compound.
- 1 38. A pharmaceutical composition according to Claim 35  
2 suitable for topical, oral or injectable administration.
- 1 39. A pharmaceutical composition according to Claim 37  
2 in the form of a liposome.
- 1 40. A method of rejuvenating the skin of a mammal  
2 comprising administering to said mammal an effective  
3 amount of the AGE-lipid according to Claim 28.
- 1 41. A method according to Claim 40 wherein the AGE-lipid  
2 is selected from the group consisting of AGE-  
3 phospholipids, AGE-low density lipoproteins, and AGE-  
4 apolipoproteins.
- 1 42. A method according to Claim 40 wherein the AGE-lipid  
2 is effective for rejuvenating the skin upon topical  
3 administration.

1 43. A method of delivering an advanced glycosylation  
2 endproduct to a biologically active site in a mammal,  
3 comprising administering to said mammal the AGE-lipid of  
4 Claim 28.

1 44. A method of delivering a drug to a biologically  
2 active site having at least one AGE receptor comprising  
3 combining said drug with the AGE-lipid of Claim 28 and  
4 administering the drug and AGE-lipid to a mammal in an  
5 amount effective for delivering said drug to said  
6 biologically active site.

1 45. A method of detecting spoilage in a lipid-containing  
2 food, comprising  
3 combining a sample of said food with an  
4 antibody which recognizes an AGE-lipid to detect the  
5 presence or amount of AGE-lipids in said sample, and  
6 comparing the amount of AGE-lipids detected to  
7 a standard.

1 46. A method for removing AGE-lipids from the body of a  
2 mammal comprising administering to said mammal the anti-  
3 antibody or second binding partner to an AGE-lipid to  
4 form an immune complex activating the animal's cellular  
5 clearance system (macrophages) to remove said immune  
6 complex and associated AGEs (advanced glycosylation  
7 endproducts).

1 47. A method according to Claim 46 wherein the AGE-lipid  
2 is selected from the group consisting of AGE-  
3 phospholipids, AGE-low density lipoproteins, and AGE-  
4 apolipoproteins.

1 48. A composition for promoting the sequestration and  
2 removal from the body of an animal of target  
3 macromolecules that have undergone advanced glycosylation  
4 comprising an AGE-lipid capable of causing the body to

5 increase its activity of recognizing and removing said  
6 macromolecules.

1 49. A test kit to be used for the detection and/or  
2 determination of one of the components selected from the  
3 group consisting of AGE-lipids, and the specific binding  
4 partners thereto, according to a predetermined protocol.

1 50. A test kit according to Claim 49, comprising:  
2 a. a labeled component which has been obtained by  
3 coupling an AGE-lipid to a detectable label;  
4 b. one or more additional immunochemical reagents  
5 of which at least one reagent is a binding partner or an  
6 immobilized binding partner, which binding partner is  
7 selected from the group consisting of:  
8 i. a binding partner capable of binding with  
9 the labeled component (a);  
10 (ii) a binding partner capable of binding with  
11 a binding partner of the labeled component (a);  
12 (iii) a binding partner capable of binding with  
13 at least one of the component(s) to be determined; and  
14 (iv) a binding partner capable of binding with  
15 at least one of the binding partners of at least one of  
16 the component(s) to be determined; and  
17 c. directions for the performance of a protocol  
18 for the detection and/or determination of one or more  
19 components of an immunochemical reaction between AGE-  
20 lipid and a specific binding partner thereto.

1 51. A test kit according to Claim 49 wherein the AGE-  
2 lipid is selected from the group consisting of AGE-  
3 phospholipids, AGE-low density lipoproteins, and AGE-  
4 apolipoproteins.


1 52. A method of detecting the presence or onset of  
2 diabetic complications which comprises measurement in a

3 patient in which such a condition is suspected of the  
4 AGE-low-density lipoprotein levels.


1 53. A method of detecting the presence or onset of  
2 atherosclerosis or other related condition which  
3 comprises measurement in a patient in which such a  
4 condition is suspected of the AGE-low-density lipoprotein  
5 levels.

1 54. A method of inhibiting the formation of oxidized  
2 lipids in a patient in need of such therapy comprising  
3 administering to said patient an effective amount of  
4 aminoguanidine or an analog thereof.

1 55. The method of Claim 54 wherein said analog is  
2 selected from the group consisting of lysine,  $\alpha$ -  
3 hydrazinohistidine and hydrazine derivatives of the  
4 formula:



8 wherein R is a group of the formula




16 and

17  $R_1$  is hydrogen or a lower alkyl group of 1-6 carbon  
18 atoms, a hydroxyethyl group, or together with  $R_2$  or  $R_4$  may  
19 be a lower alkylene bridge of 2-4 carbon atoms;

20  $R_2$  is hydrogen, amino, hydroxy, a lower alkyl group  
21 of 1-6 carbon atoms, or together with  $R_1$  or  $R_3$  is a lower  
22 alkylene bridge of 2-4 carbon atoms;  $R_2$  may also be an  
23 aminoalkylene group of the formula

76




27 wherein n is an integer of 2-7 and R<sub>6</sub> and R<sub>7</sub> are  
 28 independently a lower alkyl group of 1-6 carbon atoms or  
 29 together form a part of a cycloalkyl or heterocyclic ring  
 30 containing from 1 to 2 heteroatoms, of which at least one  
 31 is nitrogen; and the second of said heteroatoms is  
 32 selected from the group consisting of nitrogen, oxygen,  
 33 and sulfur; with the proviso that when the second of said  
 34 heteroatoms of the heterocyclic ring is nitrogen and  
 35 forms a piperazine ring; it may be optionally substituted  
 36 by a substituent that is identical to the portion of the  
 37 compound on the first nitrogen of the piperazine ring;  
 38 R<sub>3</sub> is hydrogen, a lower alkyl group of 1-6 carbon  
 39 atoms, or together with R<sub>2</sub> or R<sub>4</sub> is a lower alkylene  
 40 bridge of 2-4 carbon atoms;  
 41 R<sub>4</sub> is hydrogen, a lower alkyl group of 1-6 carbon  
 42 atoms or together with R<sub>1</sub> or R<sub>3</sub> is a lower alkylene bridge  
 43 of 2-4 carbon atoms; or an amino group;  
 44 R<sub>5</sub> is hydrogen, or a lower alkyl group of 1-6 carbon  
 45 atoms; with the proviso that at least one of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>  
 46 or R<sub>5</sub> is other than hydrogen; or R is an acyl or a lower  
 47 alkylsulfonyl group of up to 10 carbon atoms and R<sub>1</sub> is  
 48 hydrogen; and their pharmaceutically acceptable acid  
 49 addition salts.

1 56. A method according to Claim 54 wherein the advanced  
 2 glycosylation endproduct-oxidized lipids are selected  
 3 from the group consisting of AGE-phospholipids, AGE-low  
 4 density lipoproteins, and AGE-apolipoproteins.


- 1 / 15

FIG. 1



SUBSTITUTE SHEET


- 2 / 15



SUBSTITUTE SHEET

- 3 / 15


FIG. 3



SUBSTITUTE SHEET


- 4 / 15

FIG. 4




SUBSTITUTE SHEET

- 5 / 15




SUBSTITUTE SHEET

- 6 / 15



SUBSTITUTE SHEET


- 7 / 15



SUBSTITUTE SHEET

- 8 / 15


FIG. 8A



SUBSTITUTE SHEET

- 9 / 15

FIG. 8B



SUBSTITUTE SHEET

10 / 15

FIG. 9C




Fig. 9B





FIG. 9A



11 / 15

FIG. 10A




FIG. 10B





FIG. 10C



SUBSTITUTE SHEET

12 / 15





FIG. 12C




FIG. 12B






FIG. 12A




14 / 15

FIG. 13



15 / 15

FIG. 14



SUBSTITUTE SHEET

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 93/10880

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 A61K31/155 A61K31/195 A61K31/415 A61K31/70 A61K35/00  
G01N33/58 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES vol. 90, no. 14, 15 July 1993 pages 6434 - 6438 R. BUCALA ET AL. 'LIPID ADVANCED GLYCOSYLATION: PATHWAY FOR LIPID OXIDATION IN VIVO' see the whole document	1-15, 20, 21, 25-34, 52-54, 56
P,X	CLINICAL RESEARCH vol. 41, no. 2, May 1993 page 183A R. BUCALA ET AL. 'INHIBITION OF ADVANCED GLYCOSYLATION BY AMINOGUANIDINE REDUCES PLASMA LDL LEVELS IN DIABETES' see the whole document	1-13
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

22 March 1994

Date of mailing of the international search report

10.04.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Hoff, P

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 93/10880

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO,A,93 13421 (THE ROCKEFELLER UNIVERSITY) 8 July 1993 see abstract see page 16, line 12 - line 13 see page 22, line 11 - line 16; claims ---	46,47
X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES vol. 89, no. 15 , 1992 pages 6876 - 6880 S. PICARD ET AL. 'AMINOGUANIDINE INHIBITS OXIDATIVE MODIFICATION OF LOW DENSITY LIPOPROTEIN PROTEIN AND THE SUBSEQUENT INCREASE IN UPTAKE BY MACROPHAGE SCAVENGER RECEPTORS' cited in the application see the whole document ---	1-13,54, 56
Y	---	14,55
Y	EP,A,0 316 852 (THE ROCKEFELLER UNIVERSITY) 24 May 1989 cited in the application see abstract see page 6, line 48 - line 50 see page 9, line 53 - page 10, line 6; claims ---	14,55
A	DIABETE & METABOLISME vol. 17, no. 6 , 1991 pages 497 - 502 G. PONSIN ET AL. 'CONSEQUENCES METABOLIQUES DE LA GLUCOSYLATION NON ENZYMATIQUE DES APOLIPOPROTEINS' see the whole document ---	1-27, 33-51, 54-56
X	---	28-32, 52,53
A	WO,A,93 04086 (THE ROCKEFELLER UNIVERSITY) 4 March 1993 see abstract; claims 1,26,31-45 ---	15-26
A	THE JOURNAL OF BIOLOGICAL CHEMISTRY vol. 267, no. 8 , 1992 pages 5133 - 5138 Z. MAKITA ET AL. 'IMMUNOCHEMICAL DETECTION OF ADVANCED GLYCOSYLATION END PRODUCTS IN VIVO' cited in the application see the whole document ---	20-26
	---	
	-/--	

## INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/US 93/10880

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	THE NEW ENGLAND JOURNAL OF MEDICINE vol. 318, no. 20 , 1988 pages 1315 - 1321 M. BROWNLEE ET AL. 'ADVANCED GLYCOSYLATION END PRODUCTS IN TISSUE AND THE BIOCHEMICAL BASIS OF DIABETIC COMPLICATIONS'	10-13, 15,28-32
A	see the whole document	1-9,14, 16-27, 33-56
X	--- PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES vol. 87 , 1990 pages 9010 - 9014 M. KIRSTEIN ET AL. 'ADVANCED PROTEIN GLYCOSYLATION INDUCES TRANSENDOTHELIAL HUMAN MONOCYTE CHEMOTAXIS AND SECRETION OF PLATELET-DERIVED GROWTH FACTOR: ROLE IN VASCULAR DISEASE OF DIABETES AND AGING' see the whole document	28-34
X	--- DIABETOLOGIA vol. 30, no. 7 , 1987 page 568A G.P. PESCARONA ET AL. 'NONENZYMATIC GLYCOSYLATION OF MEMBRANE PHOSPHOLIPIDS: A NEW MODEL OF CELLULAR DAMAGE IN INSULIN-INSENSITIVE TISSUES' see the whole document	28-32
X	--- EP,A,0 096 439 (UNILEVER) 21 December 1983 see abstract; claims	28-34
X	--- DIABETES vol. 34, no. 9 , 1985 pages 938 - 941 M. BROWNLEE ET AL. 'NONENZYMATIC GLYCOSYLATION PRODUCTS ON COLLAGEN COVALENTLY TRAP LOW-DENSITY LIPOPROTEIN' see the whole document	28-34
Y	---	35-44, 49-51
Y	WO,A,85 04169 (THE ROCKEFELLER UNIVERSITY) 26 September 1985 see abstract; claims	49-51
Y	--- US,A,4 900 747 (VLASSARA ET AL.) 13 February 1990 see abstract	35-44
X	see column 8, line 38 - column 9, line 22 see column 10, line 3 - line 7; claims	48
	--- -/--	

# INTERNATIONAL SEARCH REPORT

Int: .nal Application No

PCT/US 93/10880

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 222 313 (THE ROCKEFELLER UNIVERSITY) 20 May 1987 see the whole document -----	1-56

# INTERNATIONAL SEARCH REPORT

Int'l. application No.

PCT/US 93/ 10880

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.: X  
because they relate to subject matter not required to be searched by this Authority, namely:  
REMARK: Although claims 1-27, 40-44, 46, 47, 52-56 are directed to a method of

treatment and to a method of diagnostic practised on the human/animal body  
the search has been carried out and based on the alleged effects of the compound/  
composition.

2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such  
an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 93/10880

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9313421	08-07-93	AU-B- 3418793	28-07-93
EP-A-0316852	24-05-89	US-A- 4908446	13-03-90
		US-A- 4983604	08-01-91
		AU-B- 622419	09-04-92
		JP-A- 2000156	05-01-90
		US-A- 4978684	18-12-90
		US-A- 5128122	07-07-92
		US-A- 5140048	18-08-92
		US-A- 5096703	17-03-92
		US-A- 5221683	22-06-93
		US-A- 5243071	07-09-93
		US-A- 5262152	16-11-93
		US-A- 5272165	21-12-93
		US-A- 5258381	02-11-93
WO-A-9304086	04-03-93	US-A- 5202424	13-04-93
		AU-A- 2506792	16-03-93
EP-A-0096439	21-12-83	AU-B- 547203	10-10-85
		AU-A- 1537083	15-12-83
		JP-A- 59001499	06-01-84
		US-A- 4547387	15-10-85
WO-A-8504169	26-09-85	US-A- 4665192	12-05-87
		AU-B- 583034	20-04-89
		AU-A- 4153185	11-10-85
		CA-A- 1250587	28-02-89
		CA-A- 1294218	14-01-92
		DE-D- 3587667	05-01-94
		EP-A, B 0175764	02-04-86
		EP-A- 0322402	28-06-89
		JP-A- 5172813	13-07-93
		JP-T- 61501706	14-08-86
		US-A- 4900747	13-02-90
		US-A- 5128360	07-07-92
		US-A- 5175192	29-12-92
		US-A- 5128122	07-07-92
		US-A- 5140048	18-08-92
		US-A- 5096703	17-03-92

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/US 93/10880

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-8504169		US-A- 5106877	21-04-92
		US-A- 5114943	19-05-92
		US-A- 5258381	02-11-93
		US-A- 5218001	08-06-93
		US-A- 5130324	14-07-92
		US-A- 5130337	14-07-92
		US-A- 5202424	13-04-93
		US-A- 4758583	19-07-88
		US-A- 5238963	24-08-93
		US-A- 5254593	19-10-93
		US-A- 5221683	22-06-93
		US-A- 5288615	22-02-94
		US-A- 5243071	07-09-93
		US-A- 5262152	16-11-93
		US-A- 5272176	21-12-93
		US-A- 5272165	21-12-93
US-A-4900747	13-02-90	US-A- 4665192	12-05-87
		US-A- 5202424	13-04-93
		AU-B- 583034	20-04-89
		AU-A- 4153185	11-10-85
		CA-A- 1250587	28-02-89
		CA-A- 1294218	14-01-92
		DE-D- 3587667	05-01-94
		EP-A, B 0175764	02-04-86
		EP-A- 0322402	28-06-89
		JP-A- 5172813	13-07-93
		JP-T- 61501706	14-08-86
		WO-A- 8504169	26-09-85
		US-A- 5128360	07-07-92
		US-A- 5175192	29-12-92
		US-A- 5128122	07-07-92
		US-A- 5140048	18-08-92
		US-A- 5096703	17-03-92
		US-A- 5106877	21-04-92
		US-A- 5114943	19-05-92
		US-A- 5258381	02-11-93
		US-A- 5218001	08-06-93
		US-A- 5130324	14-07-92
		US-A- 5130337	14-07-92

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 93/10880

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4900747		US-A- 4758583	19-07-88
		US-A- 5238963	24-08-93
		US-A- 5254593	19-10-93
		US-A- 5221683	22-06-93
		US-A- 5288615	22-02-94
		US-A- 5243071	07-09-93
		US-A- 5262152	16-11-93
		US-A- 5272176	21-12-93
		US-A- 5272165	21-12-93
		AU-B- 600306	09-08-90
		AU-A- 7827587	17-03-88
		EP-A- 0259893	16-03-88
		JP-A- 63146833	18-06-88
<hr/>			
EP-A-0222313	20-05-87	US-A- 4758583	19-07-88
		AU-B- 610056	16-05-91
		AU-A- 6495886	21-05-87
		CA-A- 1294218	14-01-92
		JP-A- 3103163	30-04-91
		JP-A- 62142114	25-06-87
		US-A- 4908446	13-03-90
		US-A- 5175192	29-12-92
		US-A- 5140048	18-08-92
		US-A- 5106877	21-04-92
		US-A- 5114943	19-05-92
		US-A- 5258381	02-11-93
		US-A- 5218001	08-06-93
		US-A- 5202424	13-04-93
		US-A- 5238963	24-08-93
		US-A- 5254593	19-10-93
		US-A- 5221683	22-06-93
		US-A- 5243071	07-09-93
		US-A- 5262152	16-11-93
		US-A- 5272176	21-12-93
		US-A- 5272165	21-12-93
<hr/>			

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**